# EDGAR Filing Document

**Accession Number:** 0001085921
**File Stem:** 0001062993-23-003723
**Filing Date:** 2023-2
**Character Count:** 185941
**Document Hash:** 1c5fc503449935f711350cb8b1645e82
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001062993-23-003723.hdr.sgml**: 20230216

**ACCESSION NUMBER**: 0001062993-23-003723

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20221031

**FILED AS OF DATE**: 20230216

**DATE AS OF CHANGE**: 20230216

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MICROMEM TECHNOLOGIES INC
- **CENTRAL INDEX KEY:** 0001085921
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER PROGRAMMING SERVICES [7371]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-26005
- **FILM NUMBER:** 23637025

**BUSINESS ADDRESS:**
- **STREET 1:** 121 RICHMOND ST W
- **STREET 2:** SUITE 602
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5H 2K1
- **BUSINESS PHONE:** 416-364-6513

**MAIL ADDRESS:**
- **STREET 1:** 121 RICHMOND ST W
- **STREET 2:** SUITE 602
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5H 2K1

------

**UNITED STATES**<br>**SECURITIES AND EXCHANGE COMMISSION** ****<br> Washington, D.C. 20549

**FORM 6-K**

**Report of Foreign Private Issuer<br>Pursuant to Rule 13a-16 or 15d-16 of<br>the Securities Exchange Act of 1934** 

**<u>February 2023</u>**

Commission File Number **0-26005**

**<u>MICROMEM TECHNOLOGIES INC.</u>**

*121 Richmond Street West, Suite 602, Toronto, ON M5H 2K1* 

[Indicate by checkmark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.]

Form 20-F [X] Form 40-F [ ]

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.]

Yes [ ]&nbsp;&nbsp;&nbsp;&nbsp; No [X]

[If "Yes" is marked, indicate below the file number assigned to the registrant in connection with rule 12g3-2(b):&nbsp;&nbsp;&nbsp;&nbsp; N/A

This report on Form 6-K is hereby incorporated by reference in the registration statement on Form F-3 (Registration No. 333-134309) of Micromem Technologies Inc. and in the prospectus contained therein, and this report on Form 6-K shall be deemed a part of such registration statement from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished by Micromem Technologies Inc. under the Securities Act of 1933 or the Securities Exchange Act of 1934.

**SIGNATURES&nbsp;&nbsp;&nbsp;&nbsp;** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | **MICROMEM TECHNOLOGIES INC.**  |
|  | **By: <u>&nbsp;&nbsp;&nbsp;&nbsp;</u>** <u>/s/ Joseph Fuda&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> |
| Date: February 15, 2023 | &nbsp;&nbsp;&nbsp;&nbsp; Name: Joseph Fuda |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title: Chief Executive Officer |

---

------

<u>**Exhibit Index**</u>

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| [99.1](exhibit99-1.htm) | [Annual Consolidated Financial Statements for the year ended October 31, 2022](exhibit99-1.htm) |
| [99.2](exhibit99-2.htm) | [Management's Discussion and Analysis for the year ended October 31, 2022](exhibit99-2.htm) |
| [99.3](exhibit99-3.htm) | [Form 52-109F1 Certification of Annual Filings Full Certificate - CEO](exhibit99-3.htm) |
| [99.4](exhibit99-4.htm) | [Form 52-109F1 Certification of Annual Filings Full Certificate - CFO](exhibit99-4.htm) |
| [99.5](exhibit99-5.htm) | [Form 13-501F1 - Class 1 Reporting Issuers and Class 3B Reporting Issuers - Participation Fee](exhibit99-5.htm) |
| [99.6](exhibit99-6.htm) | [Form 13-502F1 - Class 1 and Class 3B Reporting Issuers - Participation Fee](exhibit99-6.htm) |

---

------

## Exhibit 99.1

------

![](exhibit99-1x1x1.jpg)

**Micromem Technologies Inc.**

**Consolidated Financial Statements**

**For the years ended October 31, 2022 and 2021**

(Expressed in United States Dollars)<br>

------

**Micromem Technologies Inc.**

**Consolidated Financial Statements<br>For the years ended October 31, 2022 and 2021**<br> (Expressed in United States Dollars)

**Contents**

---

| | |
|:---|:---|
| [Report of Independent Registered Public Accounting Firm (PCAOB ID: 1930)](#page_3) | [1](#page_3) |
| Consolidated Financial Statements: |  |
| &nbsp;&nbsp;&nbsp;[Consolidated Statements of Financial Position](#page_6) | [2](#page_6) |
| &nbsp;&nbsp;&nbsp;[Consolidated Statements of Operations and Comprehensive Income (Loss)](#page_7) | [3](#page_7) |
| &nbsp;&nbsp;&nbsp;[Consolidated Statements of Changes in Equity](#page_8) | [4](#page_8) |
| &nbsp;&nbsp;&nbsp;[Consolidated Statements of Cash Flows](#page_9) | [5](#page_9) |
| &nbsp;&nbsp;&nbsp;[Notes to the Consolidated Financial Statements](#page_10) | [6](#page_10) |

---

------

---

| |
|:---|
| ![](exhibit99-1xu001.jpg) |
| **Report of Independent Registered Public Accounting Firm** |

---

<br>To the Board of Directors and Stockholders of Micromem Technologies Inc.<br>

**Opinion on the Consolidated Financial Statements**

We have audited the accompanying consolidated statements of financial position of Micromem Technologies Inc. (the "Company") as of October 31, 2022 and 2021, and the related consolidated statements of operations and comprehensive loss, changes in equity, and cash flows for each of the years in the three-year period ended October 31, 2022, and the related notes (collectively referred to as the consolidated financial statements).

In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of October 31, 2022 and 2021, and its financial performance and its consolidated cash flows for each of the years in the three-year period ended October 31, 2022, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.

**Material Uncertainty Related to Going Concern**

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. This matter is also described in the "Critical Audit Matters" section of our report.

**Basis for Opinion**

These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

**Critical Audit Matters**

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

---

| | |
|:---|:---|
| **MNP LLP** |  |
| 1 Adelaide Street East, Suite 1900, Toronto ON, M5C 2V9 | 1.877.251.2922 T: 416.596.1711 F: 416.596.7894 |

---

------

![](exhibit99-1x4x1.jpg)

**Going Concern**

*Critical Audit Matter Description*

As described in Note 2, the Company's operations are mainly funded with debt financing, which is dependent upon many external factors and may be difficult to raise when required. The Company may not have sufficient cash to fund its operations, and therefore, will require additional funding, which if not raised, may result in the delay, postponement or curtailment of some or all its activities. Management has prepared future cash flow forecasts, which involves judgement and estimation of key variables, such as planned capital expenditures, revenue, production volumes and market conditions. Future economic conditions, including the impact of the global COVID-19 pandemic and effects of key events subsequent to the year end, such as debt financing, also impacted management's judgements and estimates. We identified the Company's ability to continue as a going concern as a critical audit matter because auditing the Company's going concern assessment is complex and involves a high degree of auditor judgment to assess the reasonableness of the cash flow forecasts, planned refinancing actions and other assumptions used in the Company's going concern analysis. The Company's ability to execute the planned refinancing actions are especially judgmental given that the global financial markets and economic conditions have been, and continue to be, volatile as a result of the COVID-19 pandemic. This matter is also described in the "Material Uncertainty Related to Going Concern" section of our report.

*Audit Response*

We responded to this matter by performing procedures over management's assessment of the Company's ability to continue as a going concern. Our audit work in relation to this included, but was not restricted to, the following:

* We evaluated the cash flow forecasts prepared by management and evaluated the integrity and arithmetical accuracy of the model.

* We evaluated the key assumptions used in the model to estimate future cash flows for a reasonable period of time, not exceeding 12 months from the date of the Statements of Financial Position, by comparing assumptions used by management against historical performance, budgets, economic and industry indicators and publicly available information.

* We evaluated the key assumptions pertaining to estimated cash flows from operating activities and expected cash flows from financing activities, comparing these to available market data, underlying agreements, private placement raises and subsequent events thereafter.

* We assessed the adequacy of the going concern and COVID-19 disclosures included in Note 2 of the consolidated financial statements and consider these to appropriately reflect the assessments that management has performed.

**Valuation of Financial Instruments**

*Critical Audit Matter Description*

As described in Note 11 to the consolidated financial statements, for the year ended October 31, 2022, the Company has various convertible debentures some of which result in the recognition of derivative liabilities or equity components. Management measured the fair value of the embedded derivative liability and the fair value of host loans using the valuation techniques that require management to make several assumptions related to the inputs into those models. Auditing management's fair value determinations was challenging due to the complexity of accounting for the instruments, the related valuation models and the inputs into those models, which are highly sensitive to changes, such as volatility, risk free rates, variable conversion prices and discount rate.

*Audit Response*

We responded to this matter by performing procedures over valuation of debt instruments. Our audit work in relation to this included, but was not restricted to:

* &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We obtained and reviewed management's analysis of the financial instruments, including the assessment of the accounting for the financial instruments and the valuation methodology.

* &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We obtained signed copies of all agreements, including renewals, conversions and any new issuances and confirmed the balances and terms for a sample of the financial instruments.

---

| | |
|:---|:---|
| *1 Adelaide Street East, Suite 1900, Toronto, Ontario, M5C 2V9*<br> *1.877.251.2922 T: 416.596.1711 F: 416.596.7894 MNP.ca* | ![](exhibit99-1x5x1.jpg) |

---

------

* &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We obtained support for cash receipts related to a sample of newly issued financial instruments and cash disbursements related to a sample of repayments, and, for a sample of conversions, obtained support such as conversion notices and share issuances as confirmed with the transfer agent.

* &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We involved internal professionals with specialized skills and knowledge to assist in developing an independent implied interest rate range for a similar liability without a convertible feature and to assess the prepayment option embedded in the loans.

* &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We tested the mathematical accuracy of the valuation model and agreed certain inputs including volatility, risk free rates, variable conversion rates and discount rate to underlying source information.

---

| | |
|:---|:---|
|  | ![](exhibit99-1xu002.jpg) |
| Toronto, Ontario | Chartered Professional Accountants |
| February 15, 2023 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Licensed Public Accountants |
| We have served as the Company's auditor since 2017 |  |

---

---

| | |
|:---|:---|
| *1 Adelaide Street East, Suite 1900, Toronto, Ontario, M5C 2V9*<br> *1.877.251.2922 T: 416.596.1711 F: 416.596.7894 MNP.ca* | ![](exhibit99-1x5x1.jpg) |

---

------

**Micromem Technologies Inc. <br>Consolidated Statements of Financial Position <br>As at October 31, 2022 and October 31, 2021** <br> (Expressed in United States dollars)

---

| | | | |
|:---|:---|:---|:---|
|  | <br>**Notes** | **As at**<br>**October 31, 2022** | **As at**<br>**October 31, 2021** |
| **Assets** |  |  |  |
| Current |  |  |  |
| &nbsp;&nbsp;&nbsp;Cash | 20 | $33227 | $171397 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other receivables |  | 18200 | 24007 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets |  | 51427 | 195404 |
| Property and equipment | 6 | 48092 | 26012 |
| Patents | 7 | - | 3877 |
| &nbsp;&nbsp;&nbsp;**Total assets** |  | $99519 | $225293 |
| **Liabilities** |  |  |  |
| Current |  |  |  |
| &nbsp;&nbsp;&nbsp;Trade payables and other liabilities | 18(b), 20(c) | $287575 | $343850 |
| &nbsp;&nbsp;&nbsp;Current lease liability | 8 | 15366 | 24788 |
| &nbsp;&nbsp;&nbsp;Debenture payable | 11 | 38001 | 40207 |
| &nbsp;&nbsp;&nbsp;Convertible debentures | 1020 | 3792064 | 2452402 |
| &nbsp;&nbsp;&nbsp;Derivative liabilities | 1020 | 641299 | 787081 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities |  | 4774305 | 3648328 |
| &nbsp;&nbsp;&nbsp;Non-current lease liability | 8 | 29418 |  |
| &nbsp;&nbsp;&nbsp;Long-term loan | 9 | 43796 | 48243 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities** |  | 4847519 | 3696571 |
| **Shareholders' Deficiency** |  |  |  |
| &nbsp;&nbsp;&nbsp;Share capital | 12 | 87784725 | 86815836 |
| &nbsp;&nbsp;&nbsp;Contributed surplus |  | 27459730 | 28197382 |
| &nbsp;&nbsp;&nbsp;Equity component of convertible debentures | 10 | 793140 | 14004 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit |  | (120785595) | (118498500) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total shareholders' deficiency** |  | (4748000) | (3471278) |
| &nbsp;&nbsp;&nbsp;**Total liabilities and shareholders' deficiency** |  | $99519 | $225293 |
| Going concern | 2 |  |  |
| Contingencies | 19 |  |  |
| Subsequent events | 23 |  |  |

---

The accompanying notes are an integral part of these consolidated financial statements.

Approved on behalf of the Board of Directors: <br> <u> *"Joseph Fuda"* </u> <u> *"Alex Dey"* </u> <br> Director Director

------

**Micromem Technologies Inc.**

**Consolidated Statements of Operations and Comprehensive Loss <br>For the years ended October 31, 2022, 2021, and 2020** <br> (Expressed in United States dollars)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | | **Years ended October 31,** | **Years ended October 31,** | **Years ended October 31,** |
|  | <br>&nbsp;&nbsp;&nbsp;&nbsp;**Notes** | **2022** | **2021** | **2020** |
| **Operating expenses** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;General and administrative | 16(a) | $185366 | $155504 | $154007 |
| &nbsp;&nbsp;&nbsp;Professional, other fees and salaries | 16(b) | 647710 | 424485 | 462124 |
| &nbsp;&nbsp;&nbsp;Recovery of reserve for litigation costs |  |  |  | (205788) |
| &nbsp;&nbsp;&nbsp;Statute barred payables | 17(b) |  | (422982) |  |
| &nbsp;&nbsp;&nbsp;Stock-based compensation | 13 | 41484 | 360044 |  |
| &nbsp;&nbsp;&nbsp;Travel and entertainment |  | 59504 | 24903 | 23903 |
| &nbsp;&nbsp;&nbsp;Amortization of property and equipment | 6 | 25878 | 28033 | 27735 |
| &nbsp;&nbsp;&nbsp;Amortization of patents | 7 | 3877 | 8000 | 8123 |
| &nbsp;&nbsp;&nbsp;Foreign exchange loss (gain) | 20(a) | (176477) | 222553 | 1447 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total operating expenses** |  | 787342 | 800540 | 471551 |
| **Other expenses** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Accretion expense | 10 | 1179603 | 1169921 | 1099818 |
| &nbsp;&nbsp;&nbsp;Interest expense on convertible debt | 10 | 469425 | 495809 | 441369 |
| &nbsp;&nbsp;&nbsp;Other finance expenses | 810 | 13233 | 84478 | 35500 |
| &nbsp;&nbsp;&nbsp;Loss (gain) on revaluation of derivative liabilities | 10 | (409607) | (2547192) | (771920) |
| &nbsp;&nbsp;&nbsp;Loss (gain) on conversion of convertible debentures | 10 | 94326 | (9506) | 96484 |
| &nbsp;&nbsp;&nbsp;Loss (gain) on repayment of convertible debentures | 10 | (47877) |  |  |
| &nbsp;&nbsp;&nbsp;Loss (gain) on extinguishment of convertible debentures | 10 | 200650 | 1018928 | (127409) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total other expenses** |  | 1499753 | 212438 | 773842 |
| Loss before income tax provision |  | (2287095) | (1012978) | (1245393) |
| Income tax provision | 15 | - | - | - |
| **Net loss and comprehensive loss** |  | $(2287095) | $(1012978) | $(1245393) |
| **Weighted average number of outstanding shares, basic and diluted** | 14 | 451177796 | 422613046 | 377380476 |
| **Loss per share, basic and diluted** | 14 | $(0.01) | $- | $- |

---

The accompanying notes are an integral part of these consolidated financial statements.

------

**Micromem Technologies Inc. <br>Consolidated Statements of Changes in Equity**

**For the years ended October 31, 2022, 2021, and 2020** <br> (Expressed in United States dollars)

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | <br>**Notes** | <br>**Number** <br>**of shares** | <br>**Share**<br> **capital** | <br>**Contributed**<br>**surplus** | **Equity**<br>**component of**<br>**convertible**<br>**debentures** | <br>**Accumulated**<br>**deficit** | <br>**Total** |
| **Balance at November 1, 2019** |  | 346952721 | $84153696 | $27757639 | $50147 | $(116240129) | $(4278647) |
| &nbsp;&nbsp;&nbsp;Private placements of shares for cash | 12 | 10996994 | 425789 |  |  |  | 425789 |
| &nbsp;&nbsp;&nbsp;Convertible debentures converted into common shares | 10 | 44237644 | 859331 |  |  |  | 859331 |
| &nbsp;&nbsp;&nbsp;Expiry of convertible debenture conversion option | 10 |  |  | 52947 | (52947) |  |  |
| &nbsp;&nbsp;&nbsp;Renewal of convertible debentures | 10 |  |  |  | 26752 |  | 26752 |
| &nbsp;&nbsp;&nbsp;Shares issued on settlement of accounts payable | 12 | 365094 | 24826 |  |  |  | 24826 |
| &nbsp;&nbsp;&nbsp;Net loss |  | - | - | - | - | (1245393) | (1245393) |
| **Balance at October 31, 2020** |  | 402552453 | $85463642 | $27810586 | $23952 | $(117485522) | $(4187342) |
| &nbsp;&nbsp;&nbsp;Private placements of shares for cash | 12 | 17573429 | 840564 |  |  |  | 840564 |
| &nbsp;&nbsp;&nbsp;Convertible debentures converted into common shares | 10 | 15611852 | 511630 |  |  |  | 511630 |
| &nbsp;&nbsp;&nbsp;Expiry of convertible debenture conversion option | 10 |  |  | 26752 | (26752) |  |  |
| &nbsp;&nbsp;&nbsp;Renewal of convertible debentures | 10 |  |  |  | 16804 |  | 16804 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation | 13 |  |  | 360044 |  |  | 360044 |
| &nbsp;&nbsp;&nbsp;Net loss |  | - | - | - | - | (1012978) | (1012978) |
| **Balance at October 31, 2021** |  | 435737734 | $86815836 | $28197382 | $14004 | $(118498500) | $(3471278) |
| &nbsp;&nbsp;&nbsp;Private placements of shares for cash | 12 | 5012450 | 207588 |  |  |  | 207588 |
| &nbsp;&nbsp;&nbsp;Share issuance costs | 12 |  | (25591) |  |  |  | (25591) |
| &nbsp;&nbsp;&nbsp;Convertible debentures converted into common shares | 10 | 26443820 | 764432 |  |  |  | 764432 |
| &nbsp;&nbsp;&nbsp;Shares issued on settlement of accounts payable | 12 | 413674 | 22460 |  |  |  | 22460 |
| &nbsp;&nbsp;&nbsp;Expiry of convertible debenture conversion option | 10 |  |  | 1258388 | (1258388) |  |  |
| &nbsp;&nbsp;&nbsp;Renewal of convertible debentures | 10 |  |  | (2037524) | 2037524 |  |  |
| &nbsp;&nbsp;&nbsp;Stock-based compensation | 13 |  |  | 41484 |  |  | 41484 |
| &nbsp;&nbsp;&nbsp;Net loss |  | - | - | - | - | (2287095) | (2287095) |
| **Balance at October 31, 2022** |  | 467607678 | 87784725 | 27459730 | 793140 | (120785595) | (4748000) |

---

The accompanying notes are an integral part of these consolidated financial statements.

------

**Micromem Technologies Inc. <br>Consolidated Statements of Cash Flows**

**For the years ended October 31, 2022, 2021, and 2020** <br> (Expressed in United States dollars)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | | **Years ended October 31,** | **Years ended October 31,** | **Years ended October 31,** |
|  | <br>**Notes** | **2022** | **2021** | **2020** |
| **Operating activities** |  |  |  |  |
| Net loss |  | $(2287095) | $(1012978) | $(1245393) |
| Items not affecting cash: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Statute barred payables |  |  | (422982) |  |
| &nbsp;&nbsp;&nbsp;Amortization of property and equipment | 6 | 25878 | 28033 | 27735 |
| &nbsp;&nbsp;&nbsp;Amortization of patents | 7 | 3877 | 8000 | 8123 |
| &nbsp;&nbsp;&nbsp;Accretion expense | 1017 | 1179603 | 1169921 | 1099818 |
| &nbsp;&nbsp;&nbsp;Accrued interest on convertible debentures | 17 | 368280 | 605507 | 306839 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation | 13 | 41484 | 360044 |  |
| &nbsp;&nbsp;&nbsp;Loss (gain) on conversion of convertible debentures | 1017 | 94326 | (9506) | 96484 |
| &nbsp;&nbsp;&nbsp;Loss (gain) on repayment of convertible debentures | 1017 | (47877) |  |  |
| &nbsp;&nbsp;&nbsp;Loss (gain) on revaluation of derivative liabilities | 1017 | (409607) | (2547192) | (771920) |
| &nbsp;&nbsp;&nbsp;Loss (gain) on extinguishment of convertible debentures | 1017 | 200650 | 1018928 | (127409) |
| &nbsp;&nbsp;&nbsp;Shares issued for financing costs |  |  |  | 7500 |
| &nbsp;&nbsp;&nbsp;Foreign exchange loss (gain) | 20 | (136336) | 421937 | 78004 |
|  |  | (966817) | (380288) | (520219) |
| Net changes in non-cash working capital: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Decrease in prepaid expenses and other receivables |  | 5807 | 1414 | (10670) |
| &nbsp;&nbsp;&nbsp;Decrease in trade payables and other liabilities |  | (36021) | (383892) | (229683) |
| Cash flows used in operating activities |  | (997031) | (762766) | (760572) |
| **Investing activity** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Purchase of property and equipment | 5 | - | (5271) | - |
| Cash flows used in investing activity |  |  | (5271) |  |
| **Financing activities** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Principal payments on lease liability | 8 | (25317) | (27282) | (11422) |
| &nbsp;&nbsp;&nbsp;Proceeds from long-term loan |  |  | 17974 | 30269 |
| &nbsp;&nbsp;&nbsp;Private placements of shares for cash | 12 | 207588 | 840564 | 425789 |
| &nbsp;&nbsp;&nbsp;Share issuance costs |  | (25591) |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from issuance of convertible debentures | 17 | 765671 | 510000 | 612279 |
| &nbsp;&nbsp;&nbsp;Repayments of convertible debentures | 17 | (63490) | (593301) | (150920) |
| Cash flows provided by financing activities |  | 858861 | 747955 | 905995 |
| **Net change in cash** |  | (138170) | (20082) | 145423 |
| Cash - beginning of period |  | 171397 | 191479 | 46056 |
| **Cash - end of period** |  | $33227 | $171397 | $191479 |
| **Supplemental cash flow information** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest paid (classified in operating activities) | 10 | $88465 | $87266 | $155690 |
| &nbsp;&nbsp;&nbsp;Interest converted (classified in operating activities) | 10 | $12680 | $196964 | $- |
| &nbsp;&nbsp;&nbsp;Interest paid on non-convertible debt (classified in operating activities) |  | $9604 | $11785 | $8081 |
| &nbsp;&nbsp;&nbsp;Interest paid on lease liability (classified in operating activities) | 8 | $3629 | $9160 | $14081 |
| &nbsp;&nbsp;&nbsp;Carrying amount of convertible debentures converted into common shares | 17 | $764432 | $521136 | $762847 |
| &nbsp;&nbsp;&nbsp;Shares issued on settlement of accounts payable | 12 | $22460 | $- | $24826 |
| &nbsp;&nbsp;&nbsp;ROU asset and lease liability recognized | 8 | $48408 | $- | $- |

---

The accompanying notes are an integral part of these consolidated financial statements.

------

**Micromem Technologies Inc.**<br> **Notes to Consolidated Financial Statements**<br> **For the years ended October 31, 2022, 2021, and 2020** <br> (Expressed in United States dollars, unless otherwise noted)<br>

**1. Reporting entity and nature of business**

Micromem Technologies Inc. ("Micromem" or the "Company") is incorporated under the laws of the Province of Ontario, Canada. Micromem is a publicly traded company with its head office located at 121 Richmond Street West, Suite 602, Toronto, Ontario, Canada. The Company's common shares are currently listed on the Canadian Securities Exchange under the trading symbol "MRM" and on the Over the Counter Venture Market under the trading symbol "MMTIF".

The Company develops, based upon proprietary technology, customized sensor applications for companies (referred to as "Development Partners") operating internationally in various industry segments. The Company has not generated commercial revenues through October 31, 2022 and is devoting substantially all its efforts to securing commercial revenue opportunities.

**2. Going concern**

These consolidated financial statements have been prepared with the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future.

There are material uncertainties related to conditions and events that cast substantial doubt about the Company's ability to continue as a going concern and ultimately on the appropriateness of the use of the accounting principles applicable to a going concern. During the year ended October 31, 2022, the Company reported a net loss and comprehensive loss of $2,287,095 (2021 - $1,012,978, 2020 - $1,245,393) and negative cash flow from operations of $997,031 (2021 - $762,766, 2020 - $760,572). The Company's working capital deficiency as at October 31, 2022 was $4,722,878 (October 31, 2021 - $3,452,924).

The Company's success depends on the profitable commercialization of its proprietary sensor technology. Based upon its current operating and financial plans, management of the Company believes that it will have sufficient access to financial resources to fund the Company's planned operations through fiscal 2023; however, the ability of the Company to continue as a going concern is dependent upon its ability to secure additional financing and/or to profitably commercialize its technology. There is no assurance that the Company will be successful in the profitable commercialization of its technology, or will be able to secure the necessary additional financing. These consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern. If the going concern assumption was not appropriate for these consolidated financial statements then adjustments could be necessary to the carrying value of assets and liabilities, the reported expenses and the statement of financial position classifications used; in such cases, these adjustments could be material.

The COVID-19 pandemic creates additional risk for the Company if there is a prolonged industry slowdown in those sectors where the Company currently operates including the oil and gas sectors in particular. The Company has encountered delays in the commercial plans for its technology with its primary target customers. It secured a government backed loan of $60,000 CDN ($43,796 USD) as at October 31, 2022 (October 31, 2021 - $60,000 CDN, $48,243 USD) which matures in December 2025 (Note 9). During the year ended October 31, 2022, the Company received government wage subsidies of $nil CDN ($nil USD) (October 31, 2021 - $167,388 CDN, $133,699 USD) (Note 15(b)(i)) and rent subsidies of $nil CDN ($nil USD) (October 31, 2021 - $38,440 CDN, $30,613 USD).

**3. Basis of presentation**

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations issued by the IFRS Interpretations Committee ("IFRIC"). The Company has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective.

These consolidated financial statements were authorized for issuance and release by the Company's Board of Directors on February 14, 2023.

------

**Micromem Technologies Inc.**<br> **Notes to Consolidated Financial Statements**<br> **For the years ended October 31, 2022, 2021, and 2020** <br> (Expressed in United States dollars, unless otherwise noted)<br>

**3. Basis of presentation (continued)**

(a) Basis of consolidation

These consolidated financial statements include the accounts of Micromem Technologies Inc. and its subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation.

The Company's wholly-owned subsidiaries include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | |
|:---|:---|:---|
| (i) | **Inactive subsidiaries** | **Domiciled in** |
|  | Micromem Applied Sensors Technology Inc. ("MAST") | United States |
|  | 707019 Canada Inc. | Canada |
|  | Memtech International Inc. | Bahamas |
|  | Memtech International (USA) Inc., Pageant Technologies (USA) Inc. | United States |
|  | Pageant Technologies Inc., Micromem Holdings (Barbados) Inc. | Barbados |

---

(b) Basis of measurement

These consolidated financial statements have been prepared on the historical cost basis, except for financial instruments designated at fair value through profit and loss which are measured at their fair value.

(c) Functional and presentation currency

These consolidated financial statements are presented in United States dollars ("USD"), which is the functional currency of the Company and all of its subsidiaries.

(d) Use of estimates and judgments

The preparation of these consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates are reviewed periodically and adjustments are made as appropriate in the reporting period they become known. Items for which actual results may differ materially from these estimates are described in the following section.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Fair value of options and conversion features

The Company makes estimates and utilizes assumptions in determining the fair value for stock options and conversion features based on the application of the Black-Scholes option pricing model or the binomial option pricing model, depending on the circumstances. These pricing models require management to make various assumptions and estimates that are susceptible to uncertainty, including the volatility of the share price, expected dividend yield, expected term, risk-free interest rate, and exercise price in the binomial option pricing model.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Useful lives and recoverability of long-lived assets

Long-lived assets consist of property and equipment and patents. Amortization is dependent upon estimates of useful lives and impairment is dependent upon estimates of recoverable amounts. These are determined through the exercise of judgment and are dependent upon estimates that take into account factors such as economic and market conditions, frequency of use, anticipated changes in laws, and technological improvements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Income taxes

Income taxes and tax exposures recognized in the consolidated financial statements reflect management's best estimate of the outcome based on facts known at the reporting date. When the Company anticipates a future income tax payment based on its estimates, it recognizes a liability. The difference between the expected amount and the final tax outcome has an impact on current and deferred taxes when the Company becomes aware of this difference.

When the Company incurs losses for income tax purposes, it assesses the probability of taxable income being available in the future, based on budgeted forecasts. These forecasts are adjusted for certain non-taxable income and expenses and specific rules on the use of unused credits and tax losses. When the forecasts indicate that sufficient future taxable income will be available to deduct the temporary differences, a deferred tax asset is recognized for all deductible temporary differences.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Going concern assumption

The Company applies judgment in assessing whether material uncertainties exist that would cause doubt as to the whether the Company could continue as a going concern.

------

**Micromem Technologies Inc.**<br> **Notes to Consolidated Financial Statements**<br> **For the years ended October 31, 2022, 2021, and 2020** <br> (Expressed in United States dollars, unless otherwise noted)<br>

**4. Summary of significant accounting policies**

The principal accounting policies applied to the preparation of these consolidated financial statements are set out below:

(a) Foreign currency translation

These consolidated financial statements are presented in USD, which is the functional currency of the Company and all of its subsidiaries. At each reporting date, foreign currency denominated monetary assets and liabilities are translated at year-end exchange rates. Nonmonetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. Income, expenses, and cash flows, are translated into USD using annual average exchange rates. Exchange differences arising from operating transactions are recorded in operating profit or loss for the period; exchange differences related to financing transactions are recognized in finance income or directly in equity.

(b) Financial instruments

The Company aggregates similar financial instruments into classes based on their nature and characteristics. All financial assets except those classified as fair value through profit or loss are reviewed at each reporting date to determine whether there is any indication of impairment. Financial assets are considered to be impaired when there is objective evidence that the estimated future cash flows of the investment have been affected as a result of one or more events that occurred after the initial recognition.

The Company's accounting policy for each class of financial instruments is as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Fair value through profit or loss

Financial instruments classified as fair value through profit or loss are reported at fair value at each reporting date, and any change in fair value is recognized in net income in the period during which the change occurs. In these consolidated financial statements, cash and derivative liabilities have been classified as fair value through profit or loss.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Other financial assets and financial liabilities

Other financial instruments are carried at amortized cost using the effective interest method. Transaction costs are included in the amount initially recognized. In these consolidated financial statements, trade payables and other liabilities, debenture payable, convertible debentures, and long-term loan have been subsequently measured at amortized cost.

(c) Convertible debentures and derivative liabilities

The Company issues convertible debentures used as bridge loans, which can be converted into common shares at the option of the holder, into a fixed number of shares for a fixed amount of consideration, or into a fixed number of shares for a variable amount of consideration, or into a variable number of shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Initial recognition

For convertible debentures which provide conversion into a fixed number of shares, the liability component is recognized initially at the fair value of a similar, non-convertible liability. The equity component is recognized as the difference between the fair value of the instrument as a whole and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts.

For convertible debentures which provide conversion into a variable number of shares or into a fixed number of shares for a variable amount of consideration, the conversion option is accounted for as an embedded derivative, which is separated from the host contract. Upon initial recognition, the derivative liability is valued at fair value using a Black Scholes or a binomial pricing model. The carrying amount of the convertible debenture is recognized as the difference between the fair value of the instrument as a whole and the fair value of the derivative liability. Any directly attributable transaction costs are allocated to the derivative liability and host contract in proportion to their initial carrying amounts.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Modifications and extinguishments

To the extent there are changes to the terms of outstanding convertible debentures, these changes may be recorded as a modification or an extinguishment. A substantial change in the terms of an existing financial liability is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. The terms are substantially different if the discounted present value of the cash flows at the original effective interest rate under the new terms is at least 10% different from the discounted present value of the remaining cash flows of the original financial liability. For a modification that does not result in derecognition, a gain or loss will be recognised in profit or loss for the difference between the original contractual cash flows and the modified cash flows discounted at the original effective interest rate. For a modification that results in derecognition, a gain or loss will be recognised in profit or loss for the difference between the carrying amount of the financial liability extinguished and the fair value of the modified financial liability.

------

**Micromem Technologies Inc.**<br> **Notes to Consolidated Financial Statements**<br> **For the years ended October 31, 2022, 2021, and 2020** <br> (Expressed in United States dollars, unless otherwise noted)<br>

**4. Summary of significant accounting policies (continued)**

(d) Property and equipment

Property and equipment are recorded at cost and are amortized over their estimated useful lives at the following annual rates and methods:

---

| | | |
|:---|:---|:---|
|  | **Method** | **Rate** |
| Computers | Declining balance | &nbsp;&nbsp;&nbsp;&nbsp; 30% |
| Right-of-use asset | Straight-line | lesser of useful life and lease term (three years) |

---

(e) Impairment of long-lived assets

The Company follows the guidelines prescribed in IAS 36 with respect to the measurement for impairment of assets. The carrying amounts of property and equipment and patents are reviewed for impairment when events or changes in circumstances indicate that the carrying amounts may not be recoverable. When the carrying amount exceeds the estimated recoverable amount, the assets are written down to their recoverable amount. The recoverable amount of long-lived assets is the greater of fair value less costs to sell and value in use. Impairment losses are recognized in the consolidated statements of loss and comprehensive loss.

(f) Development costs

Research costs are expensed in the period incurred. Development costs are expensed as incurred unless they meet the criteria for capitalization. Expenditures during the development phase are capitalized if the Company can demonstrate each of the following criteria: (i) the technical feasibility of completing the asset so that it will be available for use or sale, (ii) its intention to complete the asset and use or sell it, (iii) its ability to use or sell the asset, (iv) how the asset will generate probable future economic benefits, (v) the availability of adequate technical, financial and other resources to complete the development and to use or sell the asset, and (vi) its ability to measure reliably the expenditure attributable to the asset during its development; otherwise, these costs are expensed as incurred. Costs to be recovered from development partners are recorded to development costs receivable. Payments received from development partners on projects are recorded to income as a recovery of costs incurred and reduce the outstanding receivable. There were no development costs incurred or recovery of such costs in 2022, 2021, or 2020.

(g) Patents

Patents are recorded at cost and are amortized on a straight line basis over their estimated useful lives of 5 years.

(h) Leases

At the inception of a contract, the Company assesses whether a contract is, or contains a lease. A contract is, or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. In addition, the right- of-use assets are adjusted for impairment losses, if any. The estimated useful lives and recoverable amounts of right-of-use assets are determined on the same basis as those of property and equipment. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing rate currently set at 9%. The lease liability is subsequently measured at amortized cost using the effective interest method. The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases (lease term of 12 months or less) and leases for which the underlying asset is of low value as there are none. The Company recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term.

(i) Stock-based compensation and other stock-based payments

Where equity instruments are granted to employees, they are recorded at the fair value of the equity instrument granted at the grant date. The grant date fair value is recognized in net income over the vesting period. Where equity instruments are granted to non-employees, they are recorded at the fair value of the goods or services received. When the value of goods or services received in exchange for the stock-based payment cannot be reliably estimated, the fair value is measured by use of a valuation model. The cost recognized for all equity-settled stock-based payments is reflected in contributed surplus, until the instruments are exercised. Upon exercise, shares are issued from treasury and the amount previously reflected in contributed surplus along with any proceeds paid upon exercise, are credited to share capital.

------

**Micromem Technologies Inc.**<br> **Notes to Consolidated Financial Statements**<br> **For the years ended October 31, 2022, 2021, and 2020** <br> (Expressed in United States dollars, unless otherwise noted)<br>

**4. Summary of significant accounting policies (continued)**

(j) Government grants

The Company recognises government grants when there is reasonable assurance of compliance with grant conditions and that the grants will be received. Government grants are recognised in profit or loss on a systematic basis over the periods when the related expenses are incurred and are presented in the consolidated financial statements as a reduction of these expenses. A government grant that becomes receivable as compensation for expenses already incurred is recognised in profit or loss of the period in which it becomes receivable.

(k) Income taxes

The Company accounts for its income taxes using the deferred tax assets and liabilities method. Deferred income tax assets and liabilities are determined based on the difference between the carrying amount and the tax basis of the assets and liabilities. Any change in the net amount of deferred income tax assets and liabilities is included in profit or loss or equity. Deferred income tax assets and liabilities are determined based on enacted or substantively enacted tax rates and laws which are expected to apply to taxable profit for the years in which the assets and liabilities will be recovered or settled. Deferred income tax assets are recognized when it is probable they will be realized. Deferred tax assets and liabilities are not discounted.

(l) Provisions

Provision for risks and expenses are recognized for probable outflows of resources that can be estimated and that result from present obligations resulting from past events. In the case where a potential obligation resulting from past events exists, but where occurrence of the outflow of resources is not probable or the estimate is not reliable, these contingencies are disclosed. Provisions, if any, are measured based on management's best estimates of outcomes on the basis of facts known at the reporting date.

(m) Share capital

Share capital is presented at the fair value of the shares issued or the cash amount received. Costs related to the issuance of shares are reported in equity, net of tax, as a deduction from the issuance proceeds.

(n) Earnings or loss per share

The Company presents basic and diluted earnings per share data for its common shares. Basic earnings per share is calculated by dividing the profit or loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted earnings per share is determined by adjusting the profit or loss attributable to common shareholders and the weighted average number of common shares outstanding, for the effects of all potentially dilutive common shares, which comprise stock options and convertible debentures.

**5. New accounting standards and pronouncements**

(a) Amendment to IAS 1, Presentation of Financial Statements, Issued but not yet effective

IAS 1 was amended in January 2020 to address inconsistences with how entities apply the standard over classification of current and non-current liabilities. The amendment serves to address whether, in the statement of financial position, debt and other liabilities with an uncertain settlement should be classified as current or non-current. The amendment is effective for annual reporting periods beginning on or after January 1, 2023. Earlier adoption is permitted. The Company will adopt this amendment as of the effective date, and does not anticipate any material impacts on adoption.

(b) Amendment to IAS 37, Provisions, Contingent Liabilities and Contingent Assets, Issued but not yet effective

IAS 37 was amended in May 2020 to clarify the costs a company should include as the cost of fulfilling a contract when assessing whether a contract is onerous. The amendment is effective for annual reporting periods beginning on or after January 1, 2022. Earlier adoption is permitted. The Company will adopt the amendment as of the effective date, and does not anticipate any material impacts on adoption.

(c) Amendment to IAS 16, Property, Plant and Equipment, Issued but not yet effective

IAS 16 was amended in May 2020 to prohibit deducting from the cost of an item of property, plant and equipment any proceeds from selling items produced while bringing that asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Instead, an entity recognizes the proceeds from selling such items, and the cost of producing those items, in profit or loss. The amendment is effective for annual reporting periods beginning on or after January 1, 2022. Earlier adoption is permitted. The Company will adopt the amendment as of the effective date, and does not anticipate any material impacts on adoption.

------

**Micromem Technologies Inc.**<br> **Notes to Consolidated Financial Statements**<br> **For the years ended October 31, 2022, 2021, and 2020** <br> (Expressed in United States dollars, unless otherwise noted)<br>

**5. New accounting standards and pronouncements (continued)**

(d) Amendment to IAS 8, Accounting Policies, Changes in Accounting Estimates and Errors, Issued but not yet effective

In February 2021, the International Accounting Standards Board ("IASB") issued 'Definition of Accounting Estimates' to help entities distinguish between accounting policies and accounting estimates. The amendment is effective for annual reporting periods beginning on or after January 1, 2023. Earlier adoption is permitted. The Company will adopt the amendment as of the effective date, and is currently assessing the impacts of adoption.

(e) Amendment to IFRS 9, Financial Instruments, Issued but not yet effective

The amendment clarifies the fees an entity includes in assessing the terms of a new or modified financial liability to determine whether to recognize a financial liability. The amendment clarifies that the reference to fees in the 10% test includes only fees paid or received between the borrower and the lender, including fees paid or received by either the borrower or the lender on the other's behalf (ie. finders fees, brokerage commission and legal fees are excluded). The amendment is effective for annual periods beginning on or after January 1, 2022. The Company will adopt the amendment as of the effective date, and does not anticipate any material impacts on adoption.

**6. Property and equipment**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **As at**<br>**November 1,**<br>**2021** | <br>**Additions** | <br>**Disposals** | **As at**<br>**October 31,**<br>**2022** |
| **Cost** |  |  |  |  |
| Computers | $18570 | $- | $(11104) | $7466 |
| Right-of-use assets | 74307 | 48408 | (74307) | 48408 |
|  | 92877 | 48408 | (85411) | 55874 |
| **Accumulated amortization** |  |  |  |  |
| Computers | 12824 | 1723 | (10799) | 3748 |
| Right-of-use assets | 54041 | 24155 | (74162) | 4034 |
|  | 66865 | 25878 | (84961) | 7782 |
| **Net book value** | $26012 |  |  | $48092 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **As at**<br>**November 1,**<br>**2020** | <br>**Additions** | <br>**Disposals** | **As at**<br>**October 31,**<br>**2021** |
| **Cost** |  |  |  |  |
| Computers | $32040 | $5271 | $(18741) | $18570 |
| Right-of-use assets | 74307 | - | - | 74307 |
|  | 106347 | 5271 | (18741) | 92877 |
| **Accumulated amortization** |  |  |  |  |
| Computers | 30077 | 1013 | (18266) | 12824 |
| Right-of-use assets | 27021 | 27020 | - | 54041 |
|  | 57098 | 28033 | (18266) | 66865 |
| **Net book value** | $49249 |  |  | $26012 |

---

During the year ended October 31, 2022, the Company's lease agreement pertaining to the right-of-use asset as at October 31, 2021 expired and the asset was fully depreciated and derecognized. A new lease agreement was entered into and is therefore recorded as an addition during the year ended October 31, 2022. Refer to Note 8.

------

**Micromem Technologies Inc.**<br> **Notes to Consolidated Financial Statements**<br> **For the years ended October 31, 2022, 2021, and 2020** <br> (Expressed in United States dollars, unless otherwise noted)<br>

**7. Patents**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **As at**<br>**November 1,**<br>**2021** | <br>**Additions** | <br>**Disposals** | **As at**<br>**October 31,**<br>**2022** |
| Cost | $681288 | $- | $- | $681288 |
| Accumulated amortization | 677411 | 3877 | - | 681288 |
| **Net book value** | $3877 | $(3877) | $- | $- |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **As at**<br>**November 1,**<br>**2020** | <br>**Additions** | <br>**Disposals** | **As at**<br>**October 31,**<br>**2021** |
| Cost | $681288 | $- | $- | $681288 |
| Accumulated amortization | 669411 | 8000 | - | 677411 |
| **Net book value** | $11877 | $(8000) | $- | $3877 |

---

The Company holds several patents in the United States for its Multimodal Fluid Condition Sensor Platform. In prior years, the Company had negotiated with a major automotive company and a Tier 1 manufacturer for the development and commercial exploitation of this patented technology. The Company maintains that there remains significant potential value in its existing patents in terms of potential licensing agreements and royalty fees once it begins to exploit this asset class in the future.

**8. Leases**

(a) Continuity schedule of lease obligation

The lease obligation relates to the use of office space in Toronto, Ontario. The lease agreement in effect for the years ended October 31, 2021 and 2020 was set to expire on July 31, 2022. On May 26, 2022, a new lease agreement was entered into for a term from August 1, 2022 to July 31, 2025 for office space in another location in Toronto, Ontario. The present value of the lease obligation was calculated using a discount rate of 9%.

---

| | |
|:---|:---|
| Balance, November 1, 2019 | $- |
| Adoption of IFRS 16 | 74307 |
| Interest expense | 14081 |
| Lease payments | (25504) |
| Foreign exchange | (10814) |
| Balance, October 31, 2020 | $52070 |
| Interest expense | 9160 |
| Lease payments | (36442) |
| Balance, October 31, 2021 | $24788 |
| New lease agreement | 48408 |
| Interest expense | 3629 |
| Lease payments | (28946) |
| Foreign exchange | (3095) |
| Balance, October 31, 2022 | $44784 |

---

(b) Maturity analysis of lease obligations

The following represents a maturity analysis of the Company's undiscounted contractual lease obligations as at October 31, 2022:

---

| | |
|:---|:---|
|  | **CDN** |
| Less than one year | $25532 |
| Between one and five years | $43804 |

---

------

**Micromem Technologies Inc.**<br> **Notes to Consolidated Financial Statements**<br> **For the years ended October 31, 2022, 2021, and 2020** <br> (Expressed in United States dollars, unless otherwise noted)<br>

**9. Long-term loan**

As at October 31, 2022 the Company has obtained a $60,000 CDN ($43,796 USD) (October 31, 2021 - $60,000 CDN, $48,243 USD) interest-free loan from the Government of Canada under the Canada Emergency Business Account ("CEBA") program to cover its operating costs. The term loan matures on December 31, 2025. Repaying the balance of the loan on or before December 31, 2023 will result in a loan forgiveness of $20,000 CDN ($14,599 USD). Effective January 1, 2024, any outstanding balance on the term loan shall bear interest at a rate of 5% per annum. As the Company does not yet know whether they will be able to meet the terms of forgiveness, no amount has been recognized to income.

**10. Convertible debentures**

The Company issues three types of convertible debentures: USD denominated convertible debentures with an equity component, Canadian dollar ("CDN") denominated convertible debentures with an embedded derivative due to variable consideration payable upon conversion caused by foreign exchange, and USD denominated convertible debentures with an embedded derivative caused by variable conversion prices.

During the year ended October 31, 2022, the Company incurred $21,000 financing costs (2021 - $84,478, 2020 - $35,500) which primarily consisted of early repayment and administrative fees, of which $nil (2021 - $nil, 2020 - $7,500) was converted into common shares. All loan principal amounts and conversion prices are expressed in original currency and all remaining dollar amounts are expressed in USD.

(a) Current period information presented in the consolidated financial statements

**Convertible debentures outstanding as at October 31, 2022:** <br>

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **USD**<br>**(equity**<br>**component)** | <br>**CDN (embedded**<br>**derivative)** | <br>**USD (embedded**<br>**derivative)** | <br>**Total** |
| **Loan principal outstanding** | $1205144 | $2321755 | $347700 |  |
| **Terms of loan** |  |  |  |  |
| Annual stated interest rate | 12% - 24% | 12% - 24% | 2% - 4% |  |
| Effective annual interest rate | 24% | 22 - 131% | 24% - 5803% |  |
| Conversion price to common shares | $0.03 - $0.07 | $0.05 - $0.08 | (i) - (ii) |  |
| Remaining life (in months) | 0 - 6 | 0 - 10 | 0 - 11 |  |
| **Consolidated Statement of Financial Position** |  |  |  |  |
| Carrying value of loan principal | $1203478 | $1661742 | $130424 | $2995644 |
| Interest payable | 380360 | 389617 | 26443 | 796420 |
| Convertible debentures | $1583838 | $2051359 | $156867 | $3792064 |
| Derivative liabilities | $- | $439194 | $202105 | $641299 |
| Equity component of convertible debentures | $793140 | $- | $- | $793140 |
| **For the year ended October 31, 2022:** |  |  |  |  |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **USD**<br>**(equity**<br>**component)** | <br>**CDN (embedded**<br>**derivative)** | <br>**USD (embedded**<br>**derivative)** | <br>**Total** |
| **Consolidated Statement of Operations and Comprehensive Loss** |  |  |  |  |
| Accretion expense | $28000 | $1086385 | $65218 | $1179603 |
| Interest expense | $230058 | $232211 | $7156 | $469425 |
| (Gain) loss on revaluation of derivative liabilities | $- | $(379736) | $(29871) | $(409607) |
| (Gain) loss on conversion of convertible debentures | $- | $- | $94326 | $94326 |
| (Gain) loss on repayment of convertible debentures | $- | $(661) | $(47216) | $(47877) |
| (Gain) loss on extinguishment of convertible debentures | $(28007) | $99078 | $129579 | $200650 |
| **Consolidated Statement of Changes in Equity** |  |  |  |  |
| Amount of principal converted to common shares | $- | $- | $712100 |  |
| Amount of interest converted to common shares | $- | $- | $12680 |  |
| Number of common shares issued on conversion of convertible debentures |  |  | 26443820 | 26443820 |

---

------

**Micromem Technologies Inc.**<br> **Notes to Consolidated Financial Statements**<br> **For the years ended October 31, 2022, 2021, and 2020** <br> (Expressed in United States dollars, unless otherwise noted)<br>

**10. Convertible debentures (continued)**

(a) Current period information presented in the consolidated financial statements

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Consolidated Statement of Cash Flows** |  |  |  |  |
| Amount of principal repaid in cash | $- | $7490.0 | $56000 | $63490.0 |
| Amount of interest repaid in cash | $14941 | $73524.0 | $- | $88465.0 |

---

(i) Conversion price defined as 75% multiplied by the average of the lowest 3 closing stock prices for the 10 trading days prior to conversion date.

(ii) Conversion price defined as 75% multiplied by the lowest stock price for the 20 trading days prior to conversion date.

(b) Comparative information presented in the consolidated financial statements

**Convertible debentures outstanding as at October 31, 2021:** <br>

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **USD**<br>**(equity**<br>**component)** | <br>**CDN (embedded**<br>**derivative)** | <br>**USD (embedded**<br>**derivative)** | <br>**Total** |
| **Loan principal outstanding** | $1037782 | $1989187 | $468600 |  |
| **Terms of loan** |  |  |  |  |
| Annual stated interest rate | 12% - 24% | 12% - 24% | 2% - 10% |  |
| Effective annual interest rate | 24.00% | 13% - 28735624% | 0% - 5525% |  |
| Conversion price to common shares | $0.03 - $0.07 | $0.05 - $0.08 | (i) - (ii) |  |
| Remaining life (in months) | 0 - 6 | 0 - 6 | 0 - 10 |  |
| **Consolidated Statement of Financial Position** |  |  |  |  |
| Carrying value of loan principal | $1036124 | $609924 | $172166 | $1818214 |
| Interest payable | 332605 | 269455 | 32128 | 634188 |
| Convertible debentures | $1368729 | $879379 | $204294 | $2452402 |
| Derivative liabilities | $- | $557322 | $229759 | $787081 |
| Equity component of convertible debentures | $14004 | $- | $- | $14004 |

---

(i) Conversion price defined as 75% multiplied by the average of the lowest 3 closing stock prices for the 10 trading days prior to conversion date.

(ii) Conversion price defined as 75% multiplied by the lowest stock price for the 20 trading days prior to conversion date.

**For the year ended October 31, 2021:**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **USD**<br>**(equity**<br>**component)** | <br>**CDN (embedded**<br>**derivative)** | <br>**USD (embedded**<br>**derivative)** | <br>**Total** |
| **Consolidated Statement of Operations and Comprehensive Loss** |  |  |  |  |
| Accretion expense | $28001 | $1003613 | $138307 | $1169921 |
| Interest expense | $236519 | $226520 | $32770 | $495809 |
| (Gain) loss on revaluation of derivative liabilities | $- | $(2718409) | $171217 | $(2547192) |
| (Gain) loss on conversion of convertible debentures | $- | $(47356) | $37850 | $(9506) |
| (Gain) loss on extinguishment of convertible debentures | $- | $1360536 | $(341608) | $1018928 |
| **Consolidated Statement of Changes in Equity** |  |  |  |  |
| Amount of principal converted to common shares | $- | $100000 | $284000 |  |
| Amount of interest converted to common shares | $30200 | $160064 | $6700 |  |
| Number of common shares issued on conversion of convertible debentures | 1118519 | 7744774 | 6748559 | 15611852 |

---

------

**Micromem Technologies Inc.**<br> **Notes to Consolidated Financial Statements**<br> **For the years ended October 31, 2022, 2021, and 2020** <br> (Expressed in United States dollars, unless otherwise noted)<br>

**10. Convertible debentures (continued)**

(b) Comparative information presented in the consolidated financial statements

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Consolidated Statement of Cash Flows** |  |  |  |  |
| Amount of principal repaid in cash | $205100.0 | $31492.0 | $364370.0 | $600962.0 |
| Amount of interest repaid in cash | $25101.0 | $36052.0 | $26113.0 | $87266.0 |

---

**For the year ended October 31, 2020:**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **USD**<br>**(equity**<br>**component)** | <br>**CDN (embedded**<br>**derivative)** | <br>**USD (embedded**<br>**derivative)** | <br>**Total** |
| **Consolidated Statement of Operations and Comprehensive Loss** |  |  |  |  |
| Accretion expense | $37934 | $723641 | $338244 | $1099819 |
| Interest expense | $194091 | $215923 | $31355 | $441369 |
| (Gain) loss on revaluation of derivative liabilities | $- | $(590625) | $(179295) | $(769920) |
| (Gain) loss on conversion of convertible debentures | $- | $- | $96484 | $96484 |
| (Gain) loss on extinguishment of convertible debentures | $- | $(10919) | $(116490) | $(127409) |
| **Consolidated Statement of Changes in Equity** |  |  |  |  |
| Amount of principal converted to common shares | $20000 | $35000 | $553000 | $608000 |
| Amount of interest converted to common shares | $447 | $1168 | $27046 | $28661 |
| Number of common shares issued on conversion of convertible | 511175 | 731440 | 42995029 | 44237644 |
| **Consolidated Statement of Cash Flows** |  |  |  |  |
| Amount of principal repaid in cash | $- | $93721 | $80000 | $173721 |
| Amount of interest repaid in cash | $60918 | $93005 | $1767 | $155690 |

---

(c) Fair value of derivative liabilities outstanding

The fair value of the derivative liabilities is determined in accordance with the Black-Scholes or binomial option-pricing models, depending on the circumstances. The underlying assumptions are as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **As at** | **As at** | |
|  | **October 31,** | **October 31,** | |
|  | **2022** | **2022** | **As at**<br>**October 31,**<br>**2021** |
| Share price | $0.03 | $0.03 | &nbsp;&nbsp;&nbsp; $0.05 |
| Exercise price | $0.02 - $0.07 | $0.02 - $0.07 | &nbsp;&nbsp;&nbsp;&nbsp; $0.03 - $0.07 |
| Volatility factor (based on historical volatility) | 140% | - 232% | &nbsp;&nbsp;&nbsp; 32% - 133% |
| Risk free interest rate | 3.09% | - 4.28% | &nbsp;&nbsp;&nbsp; 0.17% - 0.55% |
| Expected life of conversion features (in months) | 0 - 11 | 0 - 11 | &nbsp;&nbsp;&nbsp; 0 - 10 |
| Expected dividend yield | 0% | 0% | &nbsp;&nbsp;&nbsp; 0% |
| CDN to USD exchange rate (as applicable) | 0.7299 | 0.7299 | &nbsp;&nbsp;&nbsp;&nbsp;0.8041 |
| Call value | $0.00 | - $0.02 | &nbsp;&nbsp;&nbsp; $0.01 - $0.04 |

---

Volatility was estimated using the historical volatility of the Company's stock prices for common shares.

**11. Debenture payable**

This debenture was issued on March 17, 2020 with an original maturity date of June 17, 2020 with a principal amount of $51,500 CAD. On June 17, 2020, December 17, 2020, June 17, 2021, December 17, 2021, June 17, 2022, and December 17, 2022, the debenture was extended for six month intervals. The most recent extension on December 17, 2022, extended the debenture to June 17, 2023. The debenture bears interest at a rate of 24% and is unsecured. Interest expense on this debenture of $9,604 USD has been recognized during the year ended October 31, 2022 (2021 - $7,261 USD, 2020 - $4,840 USD).

------

**Micromem Technologies Inc.**<br> **Notes to Consolidated Financial Statements**<br> **For the years ended October 31, 2022, 2021, and 2020** <br> (Expressed in United States dollars, unless otherwise noted)<br>

**12. Share capital**

(a) Authorized and outstanding shares

The Company has two classes of shares as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Special redeemable voting preference shares - 2,000,000 authorized, nil issued and outstanding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Common shares without par value - an unlimited number authorized. The holders of the common shares are entitled to receive dividends which may be declared from time to time, and are entitled to one vote per share at shareholder meetings of the Company. All common shares are ranked equally with regards to the Company's residual assets.

(b) Private placements

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) In 2022, the Company completed 9 private placements with investors consisting of common shares with no warrants, pursuant to prospectus and registration exemptions set forth in applicable securities law. The Company received net proceeds of $181,997 and issued a total of 5,012,450 common shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) In 2021, the Company completed 37 private placements with investors consisting of common shares with no warrants, pursuant to prospectus and registration exemptions set forth in applicable securities law. The Company received net proceeds of $840,564 and issued a total of 17,573,429 common shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) In 2020, the Company completed three private placements with investors consisting of common shares with no warrants, pursuant to prospectus and registration exemptions set forth in applicable securities law. The Company received net proceeds of $425,789 and issued a total of 10,996,994 common shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Accounts payable settled in common shares

During the year ended October 31, 2022, $22,460 (2021 - $nil, 2020 - $24,826) of accounts payable was settled in exchange for 413,674 (2021 - nil, 2020 - 365,094) common shares. There was no gain or loss recognized upon settlement.

**13. Stock options**

(a) Stock option plan

Until September 8, 2020, under the Company's fixed stock option plan (the "Plan"), the Company could grant up to 18,840,000 shares of common stock to directors, officers, employees or consultants of the Company and its subsidiaries. The exercise price of each option is equal to or greater than the market price of the Company's shares on the date of grant unless otherwise permitted by applicable securities regulations. An option's maximum term under the Plan is 10 years. Stock options are fully vested upon issuance by the Company unless the Board of Directors stipulates otherwise by Directors' resolution.

The Company held its most recent Annual General Meeting of Shareholders on September 8, 2020. The authorized limit for stock options in the Company's plan was increased from 18.84 million options to 27.5 million options at the meeting.

(b) Summary of changes <br>

---

| | | |
|:---|:---|:---|
|  | <br>**Number of options** | **Weighted average**<br>**exercise price** |
| **Outstanding at October 31, 2019** | 5730000 | $0.25 |
| Cancelled | (2040000) | 0.25 |
| Expired | (1490000) | 0.46 |
| **Outstanding at October 31, 2020** | 2200000 | $0.10 |
| Granted | 9500000 | 0.06 |
| **Outstanding at October 31, 2021** | 11700000 | $0.06 |
| Granted | 2025000 | 0.07 |
| Expired | (2000000) | 0.07 |
| **Outstanding at October 31, 2022** | 11725000 | $0.06 |

---

------

**Micromem Technologies Inc.**<br> **Notes to Consolidated Financial Statements**<br> **For the years ended October 31, 2022, 2021, and 2020** <br> (Expressed in United States dollars, unless otherwise noted)<br>

**13. Stock options (continued)**

(c) Stock options outstanding at October 31, 2022

There were nil options issued to directors and officers during the year ended October 31, 2022 (2021 - 9,500,000 options issued, 2020 - nil). Of the options granted, 525,000 options have vested, 500,000 options will vest by January 11, 2023, 500,000 options will vest by April 11, 2023, and the remaining 500,000 options will vest by July 11, 2023.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | | **Weighted average** | **Weighted average** |
| <br>**Date of issue** | <br>**Expiry date** | <br>**Number of**<br>**options** | <br>**Exercise price** | **Remaining**<br>**contractual life** |
| June 29, 2018 | June 29, 2023 | 2200000 | 0.10 | 0.7 |
| November 13, 2020 | November 13, 2025 | 6500000 | 0.05 | 3.0 |
| October 8, 2021 | October 8, 2026 | 1000000 | 0.07 | 3.9 |
| December 15, 2021 | December 15, 2023 | 25000 | 0.07 | 1.1 |
| October 11, 2022 | October 11, 2023 | 2000000 | 0.07 | 0.9 |
| **Outstanding at October 31, 2022** |  | 11725000 | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.06 | 2.3 |

---

Of the total options outstanding, 10,225,000 are exercisable as at October 31, 2022 (2021 - 11,700,000).

(d) Fair value of options issued during the year

The fair value of the stock options issued has been determined in accordance with the Black Scholes option-pricing model. Volatility was estimated using the historical volatility of the Company's stock prices for its common shares. The underlying assumptions are as follows:

---

| | | |
|:---|:---|:---|
|  | **2022** | **2021** |
| Share price at grant date | $0.03 - $0.05 | &nbsp;&nbsp;&nbsp; $0.05 |
| Exercise price | $0.07 | $0.05 - $0.07 |
| Volatility factor | 212% - 272% | 148% - 180% |
| Risk free interest rate | 0.97% - 4.33% | &nbsp;&nbsp;&nbsp; 0.75% |
| Expected life of options in years | 1 - 2 | 5 |
| Expected divided yield | 0% | &nbsp;&nbsp;&nbsp; 0% |
| Forfeiture rate | 0% | &nbsp;&nbsp;&nbsp; 0% |
| Weighted average Black Scholes value at grant date | $0.02 - $0.03 | $0.05 - $0.06 |

---

During the year ended October 31, 2022, the Company recorded an expense of $41,484 respectively to the issuance of these stock options (2021 - $360,044).

**14. Loss per share**

Basic and diluted loss per share are calculated using the following numerators and denominators:

---

| | | | |
|:---|:---|:---|:---|
| **Numerator** | **2022** | **2021** | **2020** |
| Net loss attributable to common shareholders and used in computation of basic and diluted loss per share | $(2287095) | $(1012978) | (1245393) |
| **Denominator** |  |  |  |
| Weighted average number of common shares for computation of basic and diluted loss per share | 451177796 | 422613046 | 377380476 |

---

For the years ended October 31, 2022, 2021 and 2020, all stock options and conversion features were anti-dilutive and, therefore, are excluded from the calculation of diluted loss per share.

------

**Micromem Technologies Inc.**<br> **Notes to Consolidated Financial Statements**<br> **For the years ended October 31, 2022, 2021, and 2020** <br> (Expressed in United States dollars, unless otherwise noted)<br>

**15. Income taxes**

(a) The Company has non-capital losses of approximately $32 million available to reduce future taxable income, the benefit of which has not been recognized in these consolidated financial statements. As at October 31, 2022, the tax losses expire as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Canada** | **United States** | **Total** |
| 2026.0 | $1743280 | $- | $1743280 |
| 2027.0 | 1465962 |  | 1465962 |
| 2028.0 |  |  |  |
| 2029.0 | 1502416 | 143721 | 1646137 |
| 2030.0 | 2027152 | 1880897 | 3908049 |
| 2031.0 | 1221296 | 18526 | 1239822 |
| 2032.0 | 1353513 | 325793 | 1679306 |
| 2033.0 | 1640591 | 157463 | 1798054 |
| 2034.0 | 2373379 | 679089 | 3052468 |
| 2035.0 | 2682124 | 570901 | 3253025 |
| 2036.0 | 3147625 | 441019 | 3588644 |
| 2037.0 | 2519765 | 232714 | 2752479 |
| 2038.0 | 1703454 | 317 | 1703771 |
| 2039.0 | 1523813 |  | 1523813 |
| 2040.0 | 513301 |  | 513301 |
| 2041.0 | 889381 |  | 889381 |
| 2042.0 | 1262336 | - | 1262336 |
|  | $27569388 | $4450440 | $32019828 |

---

(b) In addition, the Company has available capital loss carryforwards of approximately $1.2 million to reduce future taxable capital gains, the benefit of which has not been recognized in these consolidated financial statements. Capital losses carry forward indefinitely.

(c) Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. Significant components of the Company's deferred tax assets and liabilities are as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **2022** | **2021** | **2020** |
| Non-capital losses and other | $8485255 | $8924982 | $8232346 |
| Capital losses | 162275 | 178808 | 166316 |
| Property, equipment, patents and deferred costs | 1639306 | 1794285 | 1666788 |
|  | $10286836 | $10898075 | $10065450 |
| Deferred tax asset not recognized | (10286836) | (10898075) | (10065450) |
|  | $- | $- | $- |

---

As at October 31, 2022 and 2021, the Company assessed that it is not probable that sufficient taxable profit will be available to use deferred income tax assets based on operating losses in prior years; therefore, there are no balances carried in the consolidated statements of financial position for such assets.

(d) The reconciliation of income tax attributed to continuing operations computed at the statutory tax rates to income tax expense is as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **2022** | **2021** | **2020** |
| Loss before income taxes | $(2287095) | $(1012987) | $(1245393) |
| Statutory tax rate | 26.5% | 26.5% | 26.5% |
| Expected income tax recovery | $(606080) | $(268439) | $(330029) |
| Accretion expense and loss (gain) on convertible debentures and derivative liabilities | 269531 | (97480) |  |
| Stock-based compensation | 10992 | 95412 |  |
| Non-deductible (non-taxable) expenses and other items | (3780) | 82530 | 143550 |
| Effect of exchange rate on deferred tax assets carried forward and other | 940577 | (644649) | 38037 |
| Change in deferred tax assets not recognized | (611240) | 832626 | 148442 |
|  | $- | $- | $- |

---

------

**Micromem Technologies Inc.**<br> **Notes to Consolidated Financial Statements**<br> **For the years ended October 31, 2022, 2021, and 2020** <br> (Expressed in United States dollars, unless otherwise noted)<br>

**16. Operating expenses**

(a) General and administration

The components of general and administration expenses are as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **2022** | **2021** | **2020** |
| General and administration | $59938 | $86186 | $49702 |
| Rent and occupancy | 50907 | 15536 | 37153 |
| Office insurance | 1696 | 753 | 2024 |
| Investor relations, listing and filing fees | 64769 | 53029 | 49537 |
| Telephone | 8056 | - | 15591 |
|  | $185366 | $155504 | $154007 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Rent subsidy

The Government of Canada announced the Canada Emergency Rent Subsidy (CERS) to support eligible businesses by covering part of their commercial rent or property expenses. For the year ended October 31, 2022, the Company recognized $nil (2021 - $38,440 CDN ($30,613 USD)) (2020 - $nil) of rent subsidy under this program, which has been recorded as a reduction of rent and occupancy expenses in the consolidated statements of operations and comprehensive loss. This program ran from September 27, 2020 to October 23, 2021.

(b) Professional, other fees and salaries

The components of professional, other fees and salaries expenses are as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **2022** | **2021** | **2020** |
| Professional fees | $110933 | $107554 | $148926 |
| Consulting fees | 69563 | 132793 | 138123 |
| Salaries and benefits | 467214 | 184138 | 175075 |
|  | $647710 | $424485 | $462124 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Wage subsidy

The Canada Emergency Wage Subsidy (CEWS) was announced by the Government of Canada on March 27, 2020 to enable companies negatively impacted by COVID-19 to re-hire workers. Under this program, qualifying business can receive a subsidy for a portion of their employees' wages. For the year ended October 31, 2022, the Company recognized $nil (2021 - $167,388 CDN ($133,699 USD)) (2020 - $85,455 CDN ($63,792 USD))of wage subsidy under this program, which has been recorded as a reduction of salaries expenses in the consolidated statements of operations and comprehensive loss. This program concluded on October 23, 2021.

**17. Supplemental cash flow information**

The following provides a reconciliation of the cash flows from convertible debentures and derivative liabilities :

---

| | | | |
|:---|:---|:---|:---|
|  | **Years ended October 31,** | **Years ended October 31,** | **Years ended October 31,** |
|  | **2022** | **2021** | **2020** |
| **Balance - beginning of period** | $3239483 | $3615080 | $3364499 |
| Cash flows from financing activities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of convertible debentures | 765671 | 510000 | 612279 |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayments of convertible debentures | (63490) | (593301) | (150920) |
| Non-cash changes: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accretion expense | 1179603 | 1169921 | 1099818 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued interest on convertible debentures | 368280 | 408543 | 285679 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss (gain) on repayment of convertible debentures | (47877) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss (gain) on conversion of convertible debentures | 94326 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss (gain) on revaluation of derivative liabilities | (409607) | (2547192) | (771920) |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss (gain) on extinguishment of debt | 200650 | 1018928 | (127409) |
| &nbsp;&nbsp;&nbsp;&nbsp;Convertible debentures converted into common shares | (764432) | (521136) | (762847) |
| &nbsp;&nbsp;&nbsp;&nbsp;Renewal of convertible debentures |  | (16804) | (26752) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange loss | (129244) | 195444 | 92653 |
| **Balance - end of period** | $4433363 | $3239483 | $3615080 |

---

------

**Micromem Technologies Inc.**<br> **Notes to Consolidated Financial Statements**<br> **For the years ended October 31, 2022, 2021, and 2020** <br> (Expressed in United States dollars, unless otherwise noted)<br>

**18. Key management compensation and related party transactions**

The Company reports the following related party transactions:

(a) Key management compensation

Key management personnel are persons responsible for planning, directing and controlling activities of the Company, including officers and directors. Compensation paid or payable to these individuals (or companies controlled by such individuals) are summarized as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **2022** | **2021** | **2020** |
| Professional, other fees, and salaries | $133517 | $107201 | $17517 |
| Stock-based compensation | - | 227500 | - |
|  | $133517 | $334701 | $17517 |

---

During the year ended October 31, 2022, key management were not awarded any options. During the year ended October 31, 2021, the Company awarded 5 million stock options to key management as part of the total 9.5 million stock options issued (2020 - nil).

(b) Trade payables and other liabilities

In 2021, the Company reversed certain amounts totalling $422,982 due to the payables being statute barred. These balances carried forward from prior years and the Company derecognized these balances during the year ended October 31, 2021. Included in accounts payable is $5,650 CDN (USD - $4,139) payable to a corporation controlled by an officer of the Company as at October 31, 2022 (2021 - $nil).

(c) Convertible debentures

In January 2018, the CEO of the Company subscribed for a convertible debenture of $150,000 CDN ($114,086 USD). As at October 31, 2022, $nil CDN ($nil USD) (October 31, 2021 - $9,483 CDN, $7,657 USD) in loan principal remains outstanding.

**19. Contingencies**

(a) The Company has agreed to indemnify its directors and officers and certain of its employees in accordance with the Company's by-laws. The Company maintains insurance policies that may provide coverage against certain claims.

(b) The Company has previously reported on the lawsuit filed by Mr. Steven Van Fleet against Micromem, the Company's response to the lawsuit and its counterclaims against Mr. Van Fleet.

On April 29, 2021 the matter was resolved in Micromem's favor when the Court dismissed Mr. Van Fleet's claims and ruled that he was liable to the

Company and to MAST on their counterclaims. On June 16, 2021, the Court ruled that Micromem and MAST had established damages totaling $765,579 representing the full amount that had been requested; furthermore, the Court awarded costs and statutory prejudgment interest from May 9, 2017. On June 29, 2021 the Court entered a judgement in favor of Micromem and MAST for a total amount of $1,051,739.

With respect to the Company's efforts to collect on that Judgement, a settlement ("Settlement") was reached during October 2021. Pursuant to the Settlement, the Company received an initial one-time payment and is entitled to additional monthly payments over a period of up to six years. The Company will record those payments as and when they are received. The total amount to be received by the Company if Mr. Van Fleet makes all the required payments under the terms of the Settlement will be less than the amount of the Judgement obtained by the Company, but if Mr. Van Fleet does not comply with the terms of the Settlement, it also provides the Company a means of enforcing a larger judgement against Mr. Van Fleet that is substantially in line with the Judgement. Mr. Van Fleet has made the prescribed monthly payments each month since October 2021.

The Company is now pursuing collection of the judgement award. It will report the rcovery of this contingent asset as funds are received. In the year ended October 31, 2022 the Company has recorded a recovery of $9,040 received in the period as a reduction of legal expenses (year ended October 31, 2021 - $40,000).

------

**Micromem Technologies Inc.**<br> **Notes to Consolidated Financial Statements**<br> **For the years ended October 31, 2022, 2021, and 2020** <br> (Expressed in United States dollars, unless otherwise noted)<br>

**20. Financial risk management**

(a) Currency risk

Currency risk is the risk that the fair value of, or future cash flows from, the Company's financial instruments will significantly fluctuate due to changes in foreign exchange rates. The Company is exposed to currency risk to the extent that it incurs expenses and issues convertible debentures denominated in Canadian dollars (CDN). The Company manages currency risk by monitoring the Canadian dollar position of these monetary financial instruments on a periodic basis throughout the course of the reporting period.

As at October 31, 2022, and October 31, 2021, balances that are denominated in CDN are as follows:

---

| | | |
|:---|:---|:---|
|  | **As at**<br>**October 31,**<br>**2022**<br>**CDN** | **As at**<br>**October 31,**<br>**2021**<br>**CDN** |
| Cash | $15715 | $55950 |
| Other receivables | $13832 | $7422 |
| Trade payables and other liabilities | $393978 | $425549 |
| Convertible debentures | $2810362 | $1093684 |
| Debenture payable | $51500 | $51500 |
| Derivative liabilities | $601696 | $693143 |
| Long-term loan | $60000 | $60000 |

---

A 10% strengthening of the US dollar against the CDN would decrease net loss and comprehensive loss by $257,995 as at October 31, 2022 (October 31, 2021 - decrease net loss and comprehensive loss by $166,047). A 10% weakening of the USD against the CDN would have the opposite effect of the same magnitude.

(b) Interest rate risk

Interest rate risk is the risk that the fair value of, or future cash flows from, the Company's financial instruments will significantly fluctuate due to changes in market interest rates. The Company is exposed to interest rate risk on its interest-bearing convertible debentures. This exposure is limited due to the short-term nature of the convertible debentures.

(c) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company's policy is to review liquidity resources and ensure that sufficient funds are available to meet financial obligations as they become due. Further, the Company's management is responsible for ensuring funds exist and are readily accessible to support business opportunities as they arise. With the exception of the long-term loan, all financial liabilities are due within 1 year as at October 31, 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Trade payables

The following represents an analysis of the maturity of trade payables:

---

| | | |
|:---|:---|:---|
|  | **As at**<br>**October 31,**<br>**2022** | **As at**<br>**October 31,**<br>**2021** |
| Less than 30 days past billing date | $287575 | $384057 |
| 31 to 90 days past billing date |  |  |
| Over 90 days past billing date | - | - |
|  | $287575 | $384057 |

---

------

**Micromem Technologies Inc.**<br> **Notes to Consolidated Financial Statements**<br> **For the years ended October 31, 2022, 2021, and 2020** <br> (Expressed in United States dollars, unless otherwise noted)<br>

**20. Financial risk management (continued)**

(c) Liquidity risk (continued)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Convertible debentures and derivative liabilities

The following represents an analysis of the maturity of the convertible debentures and derivative liabilities:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **As at October 31,** | **As at October 31,** | **As at October 31,** | **As at October 31,** | **As at October 31,** | **As at October 31,** |
|  | **2022** | **2022** | **2022** | **2021** | **2021** | **2021** |
|  | | | Debenture | | | |
|  | Convertible<br>debentures | Derivative<br>liabilities | payable | Convertible<br>debentures | Derivative<br>liabilities | Debenture<br>payable |
| Less than three months | $2440840 | $162380 | $- | $1609762 | $238802 | $- |
| Three to six months | 1204783 | 257933 |  | 842451 | 414602 |  |
| Six to twelve months | 146441 | 220986 | 38001 | 189 | 133677 | 40207 |
|  | $3792064 | $641299 | $38001 | $2452402 | $787081 | $40207 |

---

(d) Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's cash. The maximum exposure to credit risk is the carrying value of these financial assets, which amounted to $33,227 as at October 31, 2022 (October 31, 2021 - $171,397). The Company reduces its credit risk by assessing the credit quality of counterparties, taking into account their financial position, past experience and other factors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Cash

The Company held cash of $33,227 at October 31, 2022 (October 31, 2021 - $171,397). The cash is held with central banks and financial institution counterparties that are highly rated. The Company has assessed no significant change in credit risk and an insignificant loss allowance.

**21. Fair value hierarchy**

Assets and liabilities recorded at fair value in the consolidated statements of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

Level 1 - valuation based on quoted prices (unadjusted) in active markets for identical assets and liabilities. There are no assets or liabilities in this category in these consolidated financial statements.

Level 2 - valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. In these consolidated financial statements, derivative liabilities are included in this category.

Level 3 - valuation techniques using the inputs for the asset or liability that are not based on observable market data. There are no assets or liabilities in this category in these consolidated financial statements.

The Company's policy for determining when transfers between levels of fair value hierarchy occur is based on the date of the event or changes in circumstances that caused the transfer. During the years ended October 31, 2022 and 2021, there were no transfers between levels.

**22. Capital risk management**

The Company's objectives when managing capital are to (i) maintain its ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders, (ii) ensure it has sufficient cash resources to further develop and market its technologies and (iii) maintain its ongoing operations. The Company defines its capital as its net assets, i.e. total assets less total liabilities. In order to secure the additional capital necessary to pursue these objectives, the Company may attempt to raise additional funds through the issuance of equity or convertible debentures or by securing strategic partners. The Company is not subject to externally imposed capital requirements and there has been no change with respect to the overall capital risk management strategy during the year ended October 31, 2022.

------

**Micromem Technologies Inc.**<br> **Notes to Consolidated Financial Statements**<br> **For the years ended October 31, 2022, 2021, and 2020** <br> (Expressed in United States dollars, unless otherwise noted)<br>

**23. Subsequent events**

Subsequent to October 31, 2022:

(a) The Company secured two (2) private placements with investors consisting of common shares with no warrants pursuant to prospectuses and registrations set forth in applicable securities law. It realized net proceeds of $50,000 CDN ($36,635 USD) and issued a total of 1,000,000 common shares.

(b) The Company secured $143,000 USD in convertible debentures with a 12 month term and conversion features which become effective six months after initiation date.

(c) The Company converted $172,584 USD of convertible debentures and accrued interest through the issuance of 7,307,524 common shares.

(d) The Company repaid $5,000 USD of interest accrued on a convertible debenture.

(e) The Company extended convertible debentures that were within 3 months of maturity date from October 31, 2022 for an additional (6) months.

------

## Exhibit 99.2

------

---

| |
|:---|
| **MICROMEM TECHNOLOGIES INC.** |
| **MANAGEMENT'S DISCUSSION AND ANALYSIS** |
| **FOR THE FISCAL YEAR ENDED OCTOBER 31, 2022**<br> **PREPARED AS OF FEBRUARY 15, 2023** |

---

**NOTICE TO READER**

The Management's Discussion and Analysis ("MD&A") report for Micromem Technologies Inc. for the fiscal year October 31, 2022, as attached, is dated as of February 15, 2023, consistent with the date of the Independent Registered Public Accounting Firm report and with the original 52-109 CEO and CFO certification filings related thereto.

---

| | |
|:---|:---|
| <u>/s/ Dan Amadori</u> | <u>/s/ Joseph Fuda</u> |
| Dan Amadori, CFO | Joseph Fuda, CEO |
| February 15, 2023 | February 15, 2023 |

---

------

---

| |
|:---|
| **MICROMEM TECHNOLOGIES INC.** |
| **MANAGEMENT'S DISCUSSION AND ANALYSIS** |
| **FOR THE FISCAL YEAR ENDED OCTOBER 31, 2022**<br> **PREPARED AS OF FEBRUARY 15, 2023**<br>|

---

**INTRODUCTION** 

The following sets out the Management's Discussion and Analysis ("MD&A") of the financial position and result of operations for the fiscal year ending October 31, 2022, of Micromem Technologies Inc. (the "Company", "Micromem" or "we"). The MD&A should be read in conjunction with the Company's audited consolidated financial statements and accompanying notes for the fiscal years ending October 31, 2022, and 2021 which are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board. Additional information regarding the Company is available on the SEDAR website at <u>www.sedar.com</u>.

The Company's shares are traded on the OTCQB under the symbol MMTIF and on the Canadian Securities Exchange ("CSE") under the symbol MRM. In November 2007, the Company incorporated Micromem Applied Sensor Technologies Inc. ("MAST") for the purpose of moving forward with the planned commercialization of its technology.

Certain information provided by the Company in this MD&A and in other documents publicly filed throughout the year that are not recitation of historical facts may constitute forward-looking statements. The words "may", "would", "could", "will", "likely", "estimate", "believe", "expect", "forecast" and similar expressions are intended to identify forward-looking statements.

Readers are cautioned that such statements are only predictions, and the actual events or results may differ materially. In evaluating such forward-looking statements, readers should specifically consider the various factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements.

**FORWARD LOOKING STATEMENTS** 

This MD&A contains forward-looking statements and forward-looking information within the meaning of applicable Canadian securities legislation ("forward looking statements"). Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, potentials, future events or performance (often, but not always, using words or phrases such as "believes", "expects" or "does not expect", "is expected", "anticipates" or "does not anticipate", or "intends" or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken or achieved) are not statements of historical fact, but are "forward-looking statements". Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, or developments in the Company's business or in its industry, to differ materially from the anticipated results, performance, achievements, or developments expressed or implied by such forward-looking statements. Forward-looking statements include disclosure regarding possible events, conditions or results of operations that are based on assumptions about future conditions, courses of action and consequences. Forward-looking statements may also include, without limitation, any statement relating to future events, conditions, or circumstances. The Company cautions you not to place undue reliance upon any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements relate to, among other things, the successful commercialization of our technology, comments about potential future revenues, joint development agreements and expectations of signed contracts with customers, etc. A number of inherent risks, uncertainties and factors affect the operations, performance and results of the Company and its business, and could cause actual results to differ materially from current expectations of estimated or anticipated events or results. Some of these risks and uncertainties include the risk of not securing required capital in future, the risks of not successfully concluding agreements with potential partners on a timely basis and the risks associated with commercializing and bringing to market our technology. These risks are affected by certain factors that are beyond the Company's control: the existence of present and possible future government regulation, competition that exists in the Company's business, uncertainty of revenues, markets and profitability, as well as those other factors discussed in this MD&A report. This list is not exhaustive of the factors that may affect any of the Company's forward-looking statements and reference should also be made to the Company's Annual Information Form (prepared and filed in the form of a Form 20-F Annual Report pursuant to The Securities Exchange Act of 1934) for a description of risk factors.

------

---

| |
|:---|
| **MICROMEM TECHNOLOGIES INC.** |
| **MANAGEMENT'S DISCUSSION AND ANALYSIS** |
| **FOR THE FISCAL YEAR ENDED OCTOBER 31, 2022**<br> **PREPARED AS OF FEBRUARY 15, 2023**<br>|

---

Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not undertake to update any forward-looking statements that are incorporated by reference herein, except in accordance with applicable securities law.

\*\*\*\*\*\*\*\*\*\*

------

---

| |
|:---|
| **MICROMEM TECHNOLOGIES INC.** |
| **MANAGEMENT'S DISCUSSION AND ANALYSIS** |
| **FOR THE FISCAL YEAR ENDED OCTOBER 31, 2022**<br> **PREPARED AS OF FEBRUARY 15, 2023**<br>|

---

<u>**TABLE OF CONTENTS**</u>:

---

| | |
|:---|:---|
| [**1. OVERVIEW**](#page_5) | [5](#page_5) |
| [**2. FINANCING**](#page_5) | [5](#page_5) |
| [**3. BUSINESS DEVELOPMENTS IN 2022**](#page_6) | [6](#page_6) |
| [4. **COMMENTARY ON CONVERTIBLE DEBENTURES**](#page_9) | [9](#page_9) |
| [**5. DISCUSSION OF OPERATING RESULTS**](#page_12) | [12](#page_12) |
| [**6. RISKS AND UNCERTAINTIES**](#page_17) | [17](#page_17) |
| [**7. GOING CONCERN**](#page_19) | [19](#page_19) |
| [**8. OTHER MATTERS**](#page_20) | [20](#page_20) |
| [**9. SUBSEQUENT EVENTS**](#page_24) | [24](#page_24) |

---

------

---

| |
|:---|
| **MICROMEM TECHNOLOGIES INC.** |
| **MANAGEMENT'S DISCUSSION AND ANALYSIS** |
| **FOR THE FISCAL YEAR ENDED OCTOBER 31, 2022**<br> **PREPARED AS OF FEBRUARY 15, 2023**<br>|

---

<u>**1. OVERVIEW**</u>

Micromem ("the Company") is a company that develops customized, proprietary sensor-based solutions for large multinational corporations. It has operated also through its wholly-owned subsidiary, Micromem Applied Sensor Technologies ("MAST"). Until August 2018, MAST was traditionally responsible for the development of market opportunities, maintaining customer relationships and the project management of the independent engineering subcontractors that it engaged once a client project was initiated. MAST has been inactive since October 31, 2018.

In 2022, the Company had positive new developments in its business initiatives. It also experienced client driven delays due to the Covid - 19 pandemic in terms of its commercialization strategies for the technology applications that it continued to pursue. It continued to deal within very tight working capital constraints and was successful in raising additional capital in 2022 and through to the date of this report.

Our litigation with Steve van Fleet, who resigned as an officer and director of the Company on August 17, 2018 was resolved in our favor in 2021 ; claims against the Company were dismissed and the Company was awarded damages in the settlement of this litigation.

<u>**2. FINANCING**</u>

In 2022 the Company secured $181,997 of financing from private placements (2021: $840,564). The Company issued 26,443,820 common shares relating to the conversion by debenture holders of their debentures totaling $764,432 during the year (2021: issued 15,611,852 common shares relating to conversion of debentures totaling $511,630).The Company issued 413,674 common shares with respect to the settlement of accounts payable in 2022 (2021: nil) .

The Company's convertible debt structure is complex with 3 broad categories of such debt: (i) $CDN denominated debt with fixed conversion prices; (ii) $US denominated debt with fixed conversion prices, and (iii) $US denominated debt with variable conversion prices. The term of the debt in each instance is typically between 4 months and 12 months. In 2022 the Company has repaid certain convertible loans at maturity when due as requested by the debenture holder or converted the debenture into common shares at the request of the debenture holder or extended the term of the debenture through negotiations with the debenture holder - in this latter case, certain terms of the loan - interest rate and/or conversion price - have, in some instances, been adjusted as part of the extension.

Under IFRS reporting, such loans require quarterly remeasurements. The application of the remeasurement methodology is very specific. This is more fully discussed in Section 4; in summary, there are several non-cash related income and expense charges that arise from such remeasurements. We recorded the following non-cash charges in the fiscal years ending October 31, 2022 and 2021 none of which impact the Company's cash flows:

------

---

| |
|:---|
| **MICROMEM TECHNOLOGIES INC.** |
| **MANAGEMENT'S DISCUSSION AND ANALYSIS** |
| **FOR THE FISCAL YEAR ENDED OCTOBER 31, 2022**<br> **PREPARED AS OF FEBRUARY 15, 2023**<br>|

---

---

| | | | |
|:---|:---|:---|:---|
|  | **2022** | **2021** | **Change** |
| Accretion expense | $1179603 | $1169921 | $9682 |
| Loss (gain) on conversion of convertible debentures | 94326 | (9506) | 103832 |
| Loss (gain) on revaluation of derivative liabilities | (409607) | (2547192) | 2137585 |
| Loss (gain) on extinguishment/repayment of convertible debentures | 200650 | 1018928 | (818278) |
| Net expense | $1064972 | $(367849) | $1432821 |

---

<u>**3. BUSINESS DEVELOPMENTS IN 2022:**</u>

(a) *Romgaz*:

The COVID-19 pandemic has resulted in delays in the execution of our commercial activity with Romgaz during the 2022 fiscal year.

We have referenced in our 2022 interim quarterly MD&A commentaries that we were awaiting initial purchase orders for the interwell tracer technology application during fiscal 2022.

Our discussions with Romgaz have been continuous on a weekly basis throughout fiscal 2022 and have continued to progress since our fiscal year end. The key go-forward points in these discussions, at the current date are as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) We are anticipating an initial purchase order for several interwell tracer devices, similar to the technology that Chevron deployed in the California field trials referenced above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Micromem will be commissioned to conduct/lead a development program to enhance and expand the analytics capabilities of the existing technology with the end goal of delivering a comprehensive analytics solution to Romgaz for its specific performance requirements in its gas wells.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Micromem and has pursued discussions whereby the technology application developed in (ii) above will be manufactured on a commercial scale in Romania. It is expected that the technology that will be manufactured in Romania will be suitable for both oil and gas well applications.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) A joint venture agreement between Micromem and Romgaz is contemplated. The working relationship between Micromem and Romgaz is expected to expand to include the development of other technology applications where Micromem has been active over the past five years. We expect to finalize these working arrangements and move forward with these initiatives in 2023. It is expected that Romgaz will provide the initial capital to launch this expanded working relationship.

In anticipation of these developments with Romgaz in 2023, Micromem is planning for its business activity to include the following components:

------

---

| |
|:---|
| **MICROMEM TECHNOLOGIES INC.** |
| **MANAGEMENT'S DISCUSSION AND ANALYSIS** |
| **FOR THE FISCAL YEAR ENDED OCTOBER 31, 2022**<br> **PREPARED AS OF FEBRUARY 15, 2023**<br>|

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Continuance of its working relationship with the developer of the interwell tracer device (ARTRA 171) technology which Chevron has successfully tested in on site testing of operating oil wells and for which we anticipate Romgaz purchase orders in 2023.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) We plan to maintain our dialogue with Chevron and may pursue certain licensing opportunities with Chevron relating to their proprietary technology in our continued work with Romgaz.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) We have established a Toronto - based engineering/product presence in cooperation with an established manufacturing and engineering group with whom we expect to have a role as a strategic partner to Micromem.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Between June 2021-August 2022, Micromem hired two engineering staff persons through the University of Toronto coop program, each for a 16-month term. The engineering staff were responsible for supporting all of Micromem's current initiatives with Chevron, Romgaz and other potential customers. We may continue this program of coop hires, as appropriate, in future.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) We will plan to add additional senior management to the Micromem team in the project management, engineering, and financial reporting areas of discipline .We will also look to recruit additional corporate directors to our Board .

(b) *Chevron:*

As previously reported, successful field testing of the interwall tracer device was conducted on-site at a California-based Chevron well site in 2019. Sample testing was conducted for a 12-month period thereafter through March 2020.

We attended the Houston- based OTC oil and gas conference in August 2021 and have maintained a current dialogue with Chevron and with other industry participants.

While Chevron has curtailed further development activity on this project after the onset of the COVID-19 pandemic; we believe it continues to have interest in our interwell tracer technology.

Once our initiative with Romgaz is launched, we plan to attempt to reengage with Chevron to assess potential current opportunities to collaborate upon with Chevron.

Senior management at Chevron has, in the past, been very supportive of Micromem's engagement with Romgaz.

(c) *Repsol S.A. ("Repsol"):*

With our additional staff resources in Toronto, we began to reconfigure the RT Lube Analyzer technology in which Repsol has previously expressed interest and for which we negotiated a letter of intent with Repsol in 2019. Since then, we have not had interaction with Repsol during the Covid 19 pandemic; this project may be restarted in future.

------

---

| |
|:---|
| **MICROMEM TECHNOLOGIES INC.** |
| **MANAGEMENT'S DISCUSSION AND ANALYSIS** |
| **FOR THE FISCAL YEAR ENDED OCTOBER 31, 2022**<br> **PREPARED AS OF FEBRUARY 15, 2023**<br>|

---

(d) *Covid 19 update*:

The impact on the Company's internal operations of the COVID-19 pandemic during the 2022 fiscal year is discussed below; we believe have taken the appropriate steps to maintain our business and to protect our 5 person staff to ensure their wellbeing:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) We closed the office in mid-March 2020. We relocated to smaller office premises in 2022 and the office is now open 1-2 days per week. Our staff is primarily working remotely from their homes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) We utilized the Canada Emergency Wage Subsidy program from the Canadian Federal Government to support our payroll obligations from April 2020 through October 2021 and received total subsidies of $167,388 ($133,699 USD) under this program (no additional subsidies in 2022).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) We utilized the Canada Emergency Bank Account loan program and have secured term loans totaling $60,000 CDN ($48,243 USD) which is as described in our consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) We utilized the Canada Emergency Rent Subsidy program to support our office rental expense obligations between June 2020 and September 2021and received total subsidies of $38,440 ($30,613 USD) under this program (no additional subsidies in 2022).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) Business related travel was significantly reduced after March 2020 through October 2021; it has resumed in 2022 with the continued development of the Romgaz project.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) Senior management have continued at reduced remuneration levels in 2021 and 2022.

There remains some uncertainty as to the continuation and duration of the pandemic. If the pandemic continues and remains a significant business risk for an extended period of time in 2023 and beyond, there may be additional repercussions to the Company's ongoing business which could be significant.

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

------

---

| |
|:---|
| **MICROMEM TECHNOLOGIES INC.** |
| **MANAGEMENT'S DISCUSSION AND ANALYSIS** |
| **FOR THE FISCAL YEAR ENDED OCTOBER 31, 2022**<br> **PREPARED AS OF FEBRUARY 15, 2023**<br>|

---

<u>**4. COMMENTARY ON CONVERTIBLE DEBENTURES:**</u>

*This section of the report is intended to provide readers with additional information as to the nature of the reporting requirements, procedures, and impact of the convertible debt financings that the Company has completed. The objective is to facilitate the reader's understanding of this complex aspect of the Company's financial statements.*

<u>**(1) Overview: convertible debenture reporting**</u>

(a) We are required under IFRS reporting standards to measure the components of our convertible debt including the debt, the derivative liability, and the equity component of the face value of the debt, as appropriate, upon execution of the loan agreement with the lender.

(b) The measurement methodology that we employ is in accordance with prescribed guidelines under IFRS and International Accounting Guidelines. This methodology is either a Black Scholes pricing model or a binomial distribution measurement model, depending on which model is more suitable in each case. That determination is based on a subjective assessment by the Company.

(c) When we secure a convertible debenture from an investor, the terms which are finalized through negotiation with the investor will vary on a case-by-case basis in terms of the following aspects:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Term (typically 2 months to 12 months).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Interest rate (typically 1 to 2% per month but, in some cases, between 5% - 10% per annum).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Conversion price (which may be fixed at initiation date or fixed at conversion date based on a formulaic calculation, denominated in Canadian dollars or U.S. Dollars, the latter being the functional currency of the Company and its subsidiaries).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) The option for the Company to prepay the loan during the entire term of the loan or within an initial period of the term of the loan (typically up to 6 months).

(d) At maturity date of the debenture, the debenture holder may agree to extend the term of the loan for an additional period of time, either on the same basic terms as already exist or on renegotiated terms.

------

---

| |
|:---|
| **MICROMEM TECHNOLOGIES INC.** |
| **MANAGEMENT'S DISCUSSION AND ANALYSIS** |
| **FOR THE FISCAL YEAR ENDED OCTOBER 31, 2022**<br> **PREPARED AS OF FEBRUARY 15, 2023**<br>|

---

<u>**(2) Accounting measurements and periodic reporting of convertible debentures:**</u>

(a) To the extent that there is a derivative liability that arises in the initial measurement (1(a) above), we are required to revalue the derivative liability at each quarter end using prescribed Black Scholes or binomial methodology. Then, at each reporting period , we are required to report this gain or loss on the revaluation in our consolidated statements of income.

(b) To the extent that the face value of the loan - which is due at the maturity date - is greater than the amount that is assigned to the loan component of the total amount at inception of the loan (1(a) above), then this difference must be accreted over the term of the loan. Typically, the loan term is from 2 months to 12 months. Thus, over the term of the loan, we are required to report this accretion amount as an expense in our quarterly consolidated statements of income.

(c) To the extent that a loan is converted into common shares by the debenture holder, we will close out the loan at that point, record remaining accretion expense up to the date of conversion, remeasure the derivative liability and calculate a net gain or loss on conversion of the loan. The net gain or loss is reported in our consolidated statements of income.

<u>**(3) Impact on financial reporting:**</u>

The realities and complexities of this prescribed accounting treatment gives rise to complicated disclosures in our financial statements and footnotes:

(a) We report substantial accretion expense in our audited financial statements.

(b) Over time, barring significant volatility in the share price, we generally report a gain on the settlement of the derivative liabilities. However, the quarterly revaluations of the derivative liabilities result in significant interim fluctuations.

(c) The calculated *effective interest rate* on debt can be substantial. To illustrate,(for example) if the reported fair value of the debt is a small fraction of the face value at inception and it must be accreted to face value over the term (for example 2 months), then the effective rate of interest can be very high in these reported financials, as representing the rate that would be required to step up the reported value to the face value in the short period of the term of the loan.

***It is essential, when reviewing our audited consolidated statements, to bear in mind the following:***

a) Accretion expense is a *non- cash item*.

b) Gain or loss on revaluation of derivatives in a *non -cash item.*

c) Gain or loss on extinguishment of debentures *is a non -cash item*.

d) Gain or loss on conversion of debentures to common shares is a *non -cash item.*

------

---

| |
|:---|
| **MICROMEM TECHNOLOGIES INC.** |
| **MANAGEMENT'S DISCUSSION AND ANALYSIS** |
| **FOR THE FISCAL YEAR ENDED OCTOBER 31, 2022**<br> **PREPARED AS OF FEBRUARY 15, 2023**<br>|

---

The net non -cash expense (income) relating to items (a) - (d) above reported in the fiscal year ended October 31, 2022 was ($1,064,972) (2021: $367,849; 2020: $296,973).

**(4) Additional Comments:**

The Company notes the following:

a) We have had to resort to convertible debentures financing as a primary means of securing financing over the past several years in order to continue our operations.

b) The *actual interest expense* on our convertible debentures which is interest paid to the debenture holders, is at a coupon rate typically ranging between *1% and 2%* per month. The effective rate referenced above is an accounting measurement metric, not a payable obligation.

c) The use of convertible debentures has served to increase our outstanding number of shares over the past few years.

In 2022 the Company issued 26,443,820 common shares in settlement of $764,432 of debentures which were converted to common shares by the debenture holders (2021: 15,611,852 common shares in settlement of $511,630 of converted debentures; 2020: 44,237,644 common shares in settlement of $859,351 of converted debentures).

The Company plans to deemphasize or eliminate this complex and expensive source of financing in future as it develops and grows its business and is better able to secure more conventional, lower cost financing.

\*\*\*\*\*\*\*\*\*\*

------

---

| |
|:---|
| **MICROMEM TECHNOLOGIES INC.** |
| **MANAGEMENT'S DISCUSSION AND ANALYSIS** |
| **FOR THE FISCAL YEAR ENDED OCTOBER 31, 2022**<br> **PREPARED AS OF FEBRUARY 15, 2023**<br>|

---

<u>**5. DISCUSSION OF OPERATING RESULTS:**</u>

***(a)** **Financial Position as at October 31, 2022:***

---

| | | |
|:---|:---|:---|
|  | **October 31, 2022** | **October 31, 2021** |
|  | **(US $000)** | **(US $000)** |
| **Assets:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash | 33 | 171 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other receivables | 18 | 24 |
|  | 51 | 195 |
| &nbsp;&nbsp;&nbsp;&nbsp;Property and equipment, net | 48 | 26 |
| &nbsp;&nbsp;&nbsp;&nbsp;Patents, net |  | 4 |
|  | 99 | 225 |
| **Liabilities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and other liabilities | 326 | 384 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current lease liability | 15 | 25 |
| &nbsp;&nbsp;&nbsp;&nbsp;Convertible debentures | 3792 | 2452 |
| &nbsp;&nbsp;&nbsp;&nbsp;Derivative liability | 641 | 787 |
|  | 4774 | 3648 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term lease liability | 29 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term lease loan | 44 | 49 |
|  | 4847 | 3697 |
| **Shareholders' Equity:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share capital | 87785 | 86816 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contributed surplus | 27460 | 28197 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity component of bridge loans | 793 | 14 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deficit | (120786) | (118499) |
|  | (4748) | (3472) |
|  | 99 | 225 |

---

------

---

| |
|:---|
| **MICROMEM TECHNOLOGIES INC.** |
| **MANAGEMENT'S DISCUSSION AND ANALYSIS** |
| **FOR THE FISCAL YEAR ENDED OCTOBER 31, 2022**<br> **PREPARED AS OF FEBRUARY 15, 2023**<br>|

---

<u>Commentary:</u>

---

| | |
|:---|:---|
| 1. | The Company's working capital deficiency is $4,722,878 on October 31, 2022 (2021: deficiency of $3,452,924).  |
| 2<br>| In 2019 the Company evaluated its patent portfolio and its go forward strategy for its intellectual property portfolio. It decided that it would suspend its provisional patent filings in jurisdictions outside the United States where it has been issued several patents.<br> For financial reporting purposes the Company recorded an impairment reserve of $223,143 in 2019 and it reflects an amortized value of $nil as its patent assets at October 31, 2022 (2021: $3,877). The Company believes that its patents remain as an asset to be exploited in future through the pursuit of licensing agreements with potential strategic partners. |
| 3. | The Company continued to secure additional financing in 2022 through convertible bridge loans. Given the terms of the bridge loans, the Company has measured, as appropriate, the prescribed accounting treatment for these bridge loans and the related derivatives. These loans were typically of a short-term nature and, in many cases, renewed on multiple occasions; the related financial reporting has become progressively more complex. Refer to Section 4 of this report for additional commentary. |
|  | The balance reported as bridge loans at October 31, 2022, is $3,792,064 (2021: $2,452,402) and the related derivative liability balance is $641,299 (2021: $787,081). The Company reports accretion expense on these debentures of $1,179,603 (2021: $1,169,921), a gain on the conversion of bridge loans to share capital of $94,326 (2021: $9,506), a gain on the revaluation of the underlying derivative liabilities of $409,607 (2021: $2,547,192) and a loss on extinguishment of convertible debentures of $200,650 (2021: loss of $1,018,928). Management generally employs a Black Scholes valuation model although, for certain of the loan transactions contracted for, it uses a binomial measurement model.<br> Management acknowledges that the cost of financing to the Company is significant; interest on the bridge loans is substantial. In 2022 we reported $469,425 of interest expense on convertible debt obligations (2021: $495,809). |

---

During the 2022 and 2021 fiscal years, the Company secured funding from various sources, the significant components include:

---

| | | |
|:---|:---|:---|
|  | 2022 | 2021 |
| Private placements of shares for cash consideration | $207588.0 | $840567.0 |
| Bridge loan financing | $765671.0 | $510000.0 |
| Settlements for share consideration | $764432.0 | $511630.0 |
|  | $1737691.0 | $1862197.0 |

---

------

---

| |
|:---|
| **MICROMEM TECHNOLOGIES INC.** |
| **MANAGEMENT'S DISCUSSION AND ANALYSIS** |
| **FOR THE FISCAL YEAR ENDED OCTOBER 31, 2022**<br> **PREPARED AS OF FEBRUARY 15, 2023**<br>|

---

**Operating Results:**

The following table summarizes the Company's operating results for the years ended October 31, 2022, and 2021:

**Discussion of operating Results**

---

| | | |
|:---|:---|:---|
|  | Year Ended October 31 | Year Ended October 31 |
|  | &nbsp;&nbsp;2022<br>($000) | &nbsp;&nbsp;2021<br>($000) |
| &nbsp;&nbsp;Administration | &nbsp;&nbsp;185 | &nbsp;&nbsp;156 |
| &nbsp;&nbsp;Professional fees and salaries | &nbsp;&nbsp;648 | &nbsp;&nbsp;425 |
| &nbsp;&nbsp;Recovery of settlement of AP balances | &nbsp;&nbsp;- | &nbsp;&nbsp;(423) |
| &nbsp;&nbsp;Stock-based compensation | &nbsp;&nbsp;41 | &nbsp;&nbsp;360 |
| &nbsp;&nbsp;Travel and entertainment | &nbsp;&nbsp;60 | &nbsp;&nbsp;25 |
| &nbsp;&nbsp;Amortization of property and equipment | &nbsp;&nbsp;26 | &nbsp;&nbsp;28 |
| &nbsp;&nbsp;Amortization of patents | &nbsp;&nbsp;4 | &nbsp;&nbsp;8 |
| &nbsp;&nbsp;Foreign exchange (gain) loss | &nbsp;&nbsp;(176) | &nbsp;&nbsp;222 |
| &nbsp;&nbsp;Accretion expense | &nbsp;&nbsp;1180 | &nbsp;&nbsp;1169 |
| &nbsp;&nbsp;Interest expense convertible debt | &nbsp;&nbsp;469 | &nbsp;&nbsp;496 |
| &nbsp;&nbsp;Other financing costs | &nbsp;&nbsp;13 | &nbsp;&nbsp;84 |
| &nbsp;&nbsp;Loss (gain) on revaluation of derivatives liabilities | &nbsp;&nbsp;(410) | &nbsp;&nbsp;(2547) |
| &nbsp;&nbsp;Loss (gain) on conversion of convertible debentures | &nbsp;&nbsp;94 | &nbsp;&nbsp;(10) |
| &nbsp;&nbsp;Loss on extinguishment/repayment of convertible debentures | &nbsp;&nbsp;153 | &nbsp;&nbsp;1019 |
| &nbsp;&nbsp;Net expenses (income) | &nbsp;&nbsp;2287 | &nbsp;&nbsp;1012 |
| &nbsp;&nbsp;Net comprehensive (income) loss | &nbsp;&nbsp;(2287) | &nbsp;&nbsp;(1012) |
| &nbsp;&nbsp;Income (loss per share) | &nbsp;&nbsp;- | &nbsp;&nbsp; - |

---

**Fiscal 2022 Compared to Fiscal 2021**

a) Administration costs were $185,366 in 2022 versus $155,504 in 2021. These costs include rent and occupancy costs of $50,907 (2021: $15,536, the Company reported sublet income for a portion of its office space in 2022 and 2021; in 2021 the Company also received Federal Government Covid 19 related rent subsidies); office insurance costs of $1,696 (2021: $753; the Company did not renew its D&O insurance coverage after 2020), investor relations, listings and filing fees of $64,769 (2021: $53,029), other general and administrative expenses of $59,938 (2021: $86,168).

b) Professional and other fees and salaries costs were $647,710 in 2022 versus $424,485 in 2021. The components of these total costs include legal and audit related expenses of $110,933 in 2022 (2021: $107,554), 3<sup>rd</sup> party consulting fees were $69,563 in 2022 (2021: $132,793), staff salaries and benefits were $467,214 in 2022 (2021: $184,138).

The CFO has received $40,615 of management fees in 2022 (2021: $25,376). The CEO of the Company has received $92,902 of compensation in 2022 (2021: $81,826).

------

---

| |
|:---|
| **MICROMEM TECHNOLOGIES INC.** |
| **MANAGEMENT'S DISCUSSION AND ANALYSIS** |
| **FOR THE FISCAL YEAR ENDED OCTOBER 31, 2022**<br> **PREPARED AS OF FEBRUARY 15, 2023**<br>|

---

c) Travel and entertainment expenses were $59,504 in 2022 (2021: $24,903). We limited travel expenses in 2021 as part of a broader effort to reduce the Company's operating expenses; corporate travel has resumed in 2022.

d) In 2022, the Company awarded 2,025,000 million stock options consultants. (2021: 9.5 million stock options issued to directors, officers and consultants); the related expense of $41,484 was calculated using the Black Scholes option-pricing model (2021: $360,044).

e) Interest expense was $469,425 in 2022 versus $495,809 in 2021. This represents the actual interest expense obligations incurred by the Company based on the stated interest rates on the convertible debenture notes.

f) Amortization expense was $29,755 in 2022 consisting of $3,877 relating to patents and $25,878 relating to Capital Assets (2021: $36,033 consisting of $8,000 relating to patents and $28,033 relating to Capital Assets).

g) Financing costs were $13,233 in 2022 versus $84,478 in 2021. These expenses relate to costs associated with the convertible debenture financings which the Company completed in 2022 and 2021; there were fewer such financings in 2022.

h) The gain on foreign exchange reported in 2022 was $176,477 versus a loss of $222,553 in 2021. This included the exchange relating to the translation of $CDN denominated transactions during the year and to Canadian denominated assets and liabilities at fiscal quarter and year ends. It also included the foreign exchange relating to the initiation, renewal, conversion, and repayment of convertible debentures transactions during the fiscal years. The Canadian dollar, relative to the US dollar was $0.7509 at October 31, 2019, $0.7596 at October 31, 2020, $0.7956 at October 31, 2021 and $0.7327 at October 31, 2022.

i) The other expenses reported relate to the convertible debentures. These expenses are all non-cash expenses and compare as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **2022** | **2021** | **Change** |
| &nbsp;&nbsp;Accretion expense | $1179603 | $1169921 | $9682 |
| &nbsp;&nbsp;Loss (gain) on conversion of convertible debentures | 94326 | (9506) | 103832 |
| &nbsp;&nbsp;Loss (gain) on revaluation of derivative liabilities | (409607) | (2547192) | 2137585 |
| &nbsp;&nbsp;Loss (gain) on extinguishment/repayment of convertible debentures | 200650 | 1018928 | (818278) |
| &nbsp;&nbsp;Net expense | $1064972 | $(367849) | $1432821 |

---

------

---

| |
|:---|
| **MICROMEM TECHNOLOGIES INC.** |
| **MANAGEMENT'S DISCUSSION AND ANALYSIS** |
| **FOR THE FISCAL YEAR ENDED OCTOBER 31, 2022**<br> **PREPARED AS OF FEBRUARY 15, 2023**<br>|

---

C. Unaudited Quarterly Financial Information - Summary

---

| | | |
|:---|:---|:---|
| Three months ended<br>(unaudited) | Income<br>(loss) in<br>period<br>$| Loss <br>per<br>share <br>$|
| January 31, 2022 – 1392843 | (1392843) |  |
| April 30, 2022 – (107839) | 107839 |  |
| July 31, 2022 – 1421173 | (1421173) |  |
| October 31, 2022 – (419082) | 419082 |  |
| January 31, 2021 – 1220301 | (1220301) |  |
| April 30, 2021 – 3154574 | (3154574) |  |
| July 31, 2021 – (2102701) | 2102701 |  |
| October 31, 2021 – (1259196) | 1259196 |  |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Three months ended<br>(unaudited)** | **Working capital<br>(deficiency)** | **Capital assets<br>at NBV** | **Other Assets** | **Total Assets** | **Shareholders'<br>equity (deficit)** |
| January 31, 2022 | &nbsp;&nbsp;&nbsp;&nbsp;(4341708) | &nbsp;&nbsp;&nbsp;&nbsp; 18816 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1877 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 148789 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4368574) |
| April 30, 2022 | &nbsp;&nbsp;&nbsp;&nbsp;(3939361) | &nbsp;&nbsp;&nbsp;&nbsp; 11630 |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 93372 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3790399) |
| July 31, 2022 | &nbsp;&nbsp;&nbsp;&nbsp;(5421607) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4445 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 97504 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5463523) |
| October 31, 2022 | &nbsp;&nbsp;&nbsp;&nbsp;(4722878) | &nbsp;&nbsp;&nbsp;&nbsp; 48092 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 99519 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4748000) |
| January 31, 2021 | &nbsp;&nbsp;&nbsp;&nbsp;(4694513) | &nbsp;&nbsp;&nbsp;&nbsp; 42364 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9877 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 124318 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4698923) |
| April 30, 2021 | &nbsp;&nbsp;&nbsp;&nbsp;(7214669) | &nbsp;&nbsp;&nbsp;&nbsp; 38170 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7877 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 253940 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7318323) |
| July 31, 2021 | &nbsp;&nbsp;&nbsp;&nbsp;(4876595) | &nbsp;&nbsp;&nbsp;&nbsp; 31283 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5877 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 223528 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4887324) |
| October 31, 2021 | &nbsp;&nbsp;&nbsp;&nbsp;(3452924) | &nbsp;&nbsp;&nbsp;&nbsp; 26012 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3877 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 225293 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3471278) |

---

\*\*\*\*\*\*\*\*\*\*

------

---

| |
|:---|
| **MICROMEM TECHNOLOGIES INC.** |
| **MANAGEMENT'S DISCUSSION AND ANALYSIS** |
| **FOR THE FISCAL YEAR ENDED OCTOBER 31, 2022**<br> **PREPARED AS OF FEBRUARY 15, 2023**<br>|

---

<u>**6. RISKS AND UNCERTAINTIES**</u>

There are a number of risks which may individually or in aggregate affect the long-term commercial success of the Company, both known and unknown. An investment in the Company should be considered speculative due to the nature of the Company's activities and its current stage of development.

*Stage of Development of Technology*:

The Company has made strides in advancing its technology and in developing a product portfolio and in engaging customers in joint development projects. There remains the risk that the Company must successfully complete development work on these products to have available commercially viable products which can be licensed or sold.

*Customers' Willingness to Purchase:*

We have previously entered into joint development agreements whereby our prototype products are being subjected to rigorous testing by our partners. We expect to be successful in commercializing our product portfolio. If we are successful in doing so, our partners will then have to decide the extent to which they will adopt our technology for future use for their applications. The future revenue streams for the Company are dependent upon the rate of adoption by our customers and their willingness to do so.

*Patent Portfolio*:

The Company has previously committed time and effort and incurred significant costs with respect to the maintenance and development of our intellectual property portfolio. In 2019 it decided to abandon certain provisional patent filings in international jurisdictions which it believes does not impact on the core patent technology that the Company maintains. Given the nature of IP development, the Company is subject to continuing risks that our patents could be successfully challenged and that our patent pending files may not ultimately be granted full patent status. The Company does not have extensive in-house resources so as to manage its IP portfolio in this environment and has traditionally relied heavily on its patent attorneys for these services.

------

---

| |
|:---|
| **MICROMEM TECHNOLOGIES INC.** |
| **MANAGEMENT'S DISCUSSION AND ANALYSIS** |
| **FOR THE FISCAL YEAR ENDED OCTOBER 31, 2022**<br> **PREPARED AS OF FEBRUARY 15, 2023**<br>|

---

*Financing*:

The Company has successfully raised funding each year over to continue to support its development initiatives and fund the Company's corporate structure and overheads. The Company must continue to source financing in order to continue to support its business initiatives.

*Competitors*:

The Company is subject to competition from other entities that may have greater financial resources and more in-house technical expertise.

*Management Structure*:

The Company is highly dependent on the services of a small number of senior management team members. If one of these individuals were unavailable, the Company could encounter a difficult transition process.

*Foreign Currency Exposure*:

The Company expects to sell its products and license technologies in the United States, in Canada and abroad. It has raised financing in both $CDN and $USD. The Company has not hedged its foreign currency exposure. Foreign currency fluctuations present an ongoing risk to the business.

*COVID-19 Pandemic:*

The impact on the Company of the COVID-19 pandemic has been outlined earlier in this report, including the steps that management has taken in an attempt to maintain our operations. There remains uncertainty as to the duration of the pandemic. If the pandemic continues for an extended period of time in 2023 and beyond, there may be repercussions to the Company's ongoing business which could be significant.

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

------

---

| |
|:---|
| **MICROMEM TECHNOLOGIES INC.** |
| **MANAGEMENT'S DISCUSSION AND ANALYSIS** |
| **FOR THE FISCAL YEAR ENDED OCTOBER 31, 2022**<br> **PREPARED AS OF FEBRUARY 15, 2023**<br>|

---

<u>**7. GOING CONCERN**</u>

The consolidated financial statements have been prepared on the "going concern" basis, which presumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future.

There are material uncertainties related to conditions and events that cast significant doubt about the Company's ability to continue as a going concern for a reasonable period of time in future. During the year ended October 31, 2022, the Company reported a net loss and comprehensive loss of $(2,287,095) (2021 - $1,012,978; 2020 - $1,245,393) and negative cash flow from operations of $997,031 (2021 - $762,766; 2020 - $760,572). The Company's working capital deficiency as at October 31, 2022 is $4,722,878 (2021 - $$3,452,924).

The Company's future success depends on the profitable commercialization of its proprietary sensor technology. There is no assurance that the Company will be successful in the profitable commercialization of its technology. Based upon its current operating and financial plans, management of the Company believes that it will have sufficient access to financial resources to fund the Company's planned operations through fiscal 2023 and beyond; however, the ability of the Company to continue as a going concern is dependent on its ability to secure additional financing and/or to profitably commercialize its technology. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

The COVID 19 pandemic has had a significant impact of the Company's operations since March, 2020 as discussed in the body of this MD&A document. There remains uncertainty at this date as to the duration of the pandemic. If the pandemic continues for an extended period of time in 2023 and beyond, there may be repercussions to the Company's ongoing business which could be significant.

If the "going concern" assumption was not appropriate for these consolidated financial statements, then adjustments would be necessary to the carrying value of assets and liabilities, the reported expenses and the balance sheet classifications used; in such cases, these adjustments would be material.

\*\*\*\*\*\*\*\*\*\*

------

---

| |
|:---|
| **MICROMEM TECHNOLOGIES INC.** |
| **MANAGEMENT'S DISCUSSION AND ANALYSIS** |
| **FOR THE FISCAL YEAR ENDED OCTOBER 31, 2022**<br> **PREPARED AS OF FEBRUARY 15, 2023**<br>|

---

<u>**8. OTHER MATTERS**</u>

**(a)** <u>**Critical Accounting Policies**</u>

The accounting policies the Company believes are critical to the financial reporting process include foreign currency translation, financial instruments, compound and hybrid financial instruments, derivative liabilities, conversion features of bridge loans, patents, impairment of long-lived assets, patents, deferred development costs, revenue recognition, stock-based compensation and income taxes. These critical accounting policies are set forth in Note 4 to our consolidated financial statements as of October 31, 2022.

**(b)** <u>**Legal matters: lawsuit vs Steven Van Fleet**</u>

We have previously reported on the litigation matter relating to Mr Van Fleet, the former President of MAST , which commenced in 2018.

In 2021, the court ultimately dismissed all of Mr Van Fleet's claims , found that he was liable to Micromem and MAST on their counterclaims and ordered an inquest to determine damages. The inquest was held between June 3 - 7, 2021.

On June 16<sup>th</sup>, 2021 the court ordered that Micromem, and MAST had established damages of $765,579.35, the full amount that had been requested. Additionally, the court awarded costs and statutory prejudgement interest from May 9, 2017. On June 29<sub>th</sub>, 2021 the court entered a judgement ("Judgement") in favor of Micromem and MAST and against Mr Van Fleet in the amount of $1,051,739.83.

With respect to the Company's efforts to collect on that Judgement, a settlement ("Settlement") was reached during October 2021. Pursuant to the Settlement, the Company received an initial one-time payment and is entitled to additional monthly payments over a period of up to six years. The Company will record those payments as and when they are received. The total amount to be received by the Company if Mr. Van Fleet makes all the required payments under the terms of the Settlement will be less than the amount of the Judgement obtained by the Company, but if Mr. Van Fleet does not comply with the terms of the Settlement, it also provides the Company a means of enforcing a larger judgement against Mr. Van Fleet that is substantially in line with the Judgement.

**(c)** <u>**Contingencies and Commitments**</u>

The Company may be subject to litigation, claims and governmental and regulatory proceedings arising in the ordinary course of business. In such cases, the Company accrues a loss contingency for these matters when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. There are no such accruals reflected in the Company's accounts at October 31, 2022.

------

---

| |
|:---|
| **MICROMEM TECHNOLOGIES INC.** |
| **MANAGEMENT'S DISCUSSION AND ANALYSIS** |
| **FOR THE FISCAL YEAR ENDED OCTOBER 31, 2022**<br> **PREPARED AS OF FEBRUARY 15, 2023**<br>|

---

The Company's lease that was extended in February 2017 for five years through July 2022 expired. In August 2022 the Company moved to a smaller unit in the same commercial building pursuant to a lease from August 1, 2022 to July 31, 2025. The lease stipulates base monthly and additional rental expense of $3,943 CDN. Lease commitments are as follows - commitments less than one year of $25,532 CDN; 1 years to 5 years: $43,804.

**(d)** <u>**Off-Balance Sheet Arrangements**</u>

At October 31, 2022, the Company has no off-balance sheet financial commitments and does not anticipate entering into any contracts of such nature other than the addition of new operating leases for equipment and premises as may be required in the normal course of business.

**(e)** <u>**Share Capital**</u> 

At October 31, 2022, the Company reports 467,607,678 common shares outstanding (2021: 435,737,734). Additionally, the Company has 11,725,000 stock options outstanding with a weighted average exercise price of $0.06 per share (2021: 11,700,000 options outstanding with a weighted average exercise price of $0.06 per share).

**(f)** <u>**Management and Board of Directors**</u> 

At our most recent Annual Meeting of Shareholders held on September 8, 2020, Joseph Fuda, Oliver Nepomuceno, and Alex Dey were re-elected to serve on our Board of Directors. Brian Von Herzen was not put forward for reelection to the Board at the Annual Meeting. Joseph Fuda and Dan Amadori continue to serve as officers of the Company.

Our management team and directors, along with their 2022 remuneration, is presented as below:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **2022 remuneration** | **2022 remuneration** | **2022 remuneration** | **2022 remuneration** |
| **Individual** | **Position** | **Cash** | **Options** | **Total** |
| Joseph Fuda | President, Director | 92902 |  | 92902 |
| Oliver Nepomuceno | Director |  |  |  |
| Alex Dey | Director |  |  |  |
| Dan Amadori | CFO | 40615 |  | 40615 |
| Total |  | 133517 |  | 133517 |

---

------

---

| |
|:---|
| **MICROMEM TECHNOLOGIES INC.** |
| **MANAGEMENT'S DISCUSSION AND ANALYSIS** |
| **FOR THE FISCAL YEAR ENDED OCTOBER 31, 2022**<br> **PREPARED AS OF FEBRUARY 15, 2023**<br>|

---

**(g)** <u>**Transactions with Related Parties**</u> 

The Company reports the following related party transactions:

*Key management compensation:*

Key management personnel are persons responsible for planning, directing and controlling activities of the Company, including officers and directors. Compensation paid or payable to these individuals (or companies controlled by such individuals) is summarized as:

---

| | | | |
|:---|:---|:---|:---|
|  | **2022** | **2021** | **2020** |
| Professional, other fees and salaries | $133517 | $107202 | $17517 |
| Stock based compensation |  | 227500 |  |
|  | $133517 | $334702 | $17517 |

---

In 2022 these parties were not awarded stock options (2021 - 5 million options at an exercise price of $0.05 per share). In 2020 a total of 1.3 million common stock options previously awarded to key management were cancelled.

*Trade payables and other liabilities*:

As at October 31, 2020, the Company included $167,215 in trade payables owing to a company whose major shareholder was a director of the Company from February 2014 through September 2020 and who has also previously served as its Chief Technology Officer. The balance reported relates to alleged services provided in 2015; there have been no invoices submitted by this related party after October 31, 2015. The Company has contested these charges since 2015 and there have been no further developments in 2021. Accordingly, in 2021, the Company reversed this now statute-barred balance previously reported as an account payable. There were no further developments in 2022.

*Convertible debentures:*

In May 2019, an officer of the Company provided a short-term loan of $15,000 CDN ($11,450 USD). At October 31, 2019, $10,000 CDN ($7,582 USD) in loan principal remained outstanding. In 2021, the remaining amount of loan principal was extinguished by participation of the CEO in the private placement which the Company completed at the time. The extinguishment of the debt for the shares received in the private placement resulted in a loss on conversion of $10,600.

In January 2018, an officer of the Company provided a convertible debenture of $150,000 CDN ($114,138 USD), which was repaid in full as at October 31, 2022. Amounts remaining at October 31, 2021, $10,001 CDN ($7,509 USD); October 31, 2020; $52,319 CDN ($39,756 USD).

------

---

| |
|:---|
| **MICROMEM TECHNOLOGIES INC.** |
| **MANAGEMENT'S DISCUSSION AND ANALYSIS** |
| **FOR THE FISCAL YEAR ENDED OCTOBER 31, 2022**<br> **PREPARED AS OF FEBRUARY 15, 2023**<br>|

---

**(h)** <u>**Liquidity and Capital Resources**</u>

*Liquidity:* 

We currently report negative cash flow from operations. This result will only change once we are generating sufficient revenue from either license fees, royalties or the sale of products utilizing our technology. In 2021 and subsequent to the end of the fiscal year, the Company continued to raise additional financing.

We currently have no lines of credit in place. We must continue to obtain financing from investors or from clients in support of our development projects.

We have granted to our directors, officers, and employee's options to purchase shares at prices that are at or above market price on the date of grant. At October 31, 2022 there are 11,725,000 options outstanding at an average exercise price of $0.06 per share.

*Capital Resources:* We have no commitments for capital expenditures as of October 31, 2022.

\*\*\*\*\*\*\*\*\*\*

------

---

| |
|:---|
| **MICROMEM TECHNOLOGIES INC.** |
| **MANAGEMENT'S DISCUSSION AND ANALYSIS** |
| **FOR THE FISCAL YEAR ENDED OCTOBER 31, 2022**<br> **PREPARED AS OF FEBRUARY 15, 2023**<br>|

---

<u>**9. SUBSEQUENT EVENTS**</u>

Subsequent to October 31, 2022:

(a) The Company secured two (2) private placements with investors consisting of common shares with no warrants pursuant to prospectus and registrations set forth in applicable securities law. It realized net proceeds of $50,000 CDN ($36,635 USD) and issued a total of 1,000,000 common shares.

(b) The Company secured $143,000 USD in convertible debentures with a 12 month term and conversion features which become effective six months after initiation date.

(c) The Company converted $172,584 USD of convertible debentures and accrued interest through the issuance of 7,307,524 common shares.

(d) The Company repaid $5,000 USD of interest accrued on a convertible debenture.

(e) The Company extended convertible debentures that were within 3 months of maturity date from October 31, 2022 for an additional (6) months.

------

## Exhibit 99.3

------

**FORM 52-109F1**

**CERTIFICATION OF ANNUAL FILINGS**

**FULL CERTIFICATE**

I, Joseph Fuda, Chief Executive Officer of Micromem Technologies Inc., certify the following:

1. ***Review:*** I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated by reference in the AIF (together, the "annual filings") of Micromem Technologies Inc. (the "issuer") for the financial year ended October 31, 2022.

2. ***No misrepresentations:*** Based on my knowledge, having exercised reasonable diligence, the annual filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, for the period covered by the annual filings.

3. ***Fair presentation:*** Based on my knowledge, having exercised reasonable diligence, the annual financial statements together with the other financial information included in the annual filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the annual filings.

4. ***Responsibility:*** The issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 *Certification of Disclosure in Issuers' Annual and Interim Filings*, for the issuer.

5. ***Design:*** Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer(s) and I have, as at the financial year end

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.

------

5.1 ***Control framework:*** The control framework the issuer's other certifying officer(s) and I used to design the issuer's ICFR is *Internal Control - Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO").

5.2 **ICFR - material weakness relating to design:** *N/A*

5.3 **Limitation on scope of design:** *N/A*

6. ***Evaluation:*** The issuer's other certifying officer(s) and I have

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) evaluated, or caused to be evaluated under our supervision, the effectiveness of the issuer's DC&P at the financial year end and the issuer has disclosed in its annual MD&A our conclusions about the effectiveness of DC&P at the financial year end based on that evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) evaluated, or caused to be evaluated under our supervision, the effectiveness of the issuer's ICFR at the financial year end and the issuer has disclosed in its annual MD&A.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) our conclusions about the effectiveness of ICFR at the financial year end based on that evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) for each material weakness relating to operation existing at the financial year end

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) a description of the material weakness;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) the impact of the material weakness on the issuer's financial reporting and its ICFR; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C) the issuer's current plans, if any, or any actions already undertaken, for remediating the material weakness.

7. ***Reporting changes in ICFR:*** The issuer has disclosed in its annual MD&A any change in the issuer's ICFR that occurred during the period beginning on August 1, 2022 and ended on October 31, 2022 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.

8. ***Reporting to the issuer's auditors and board of directors or audit committee:*** The issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of ICFR, to the issuer's auditors, and the board of directors or the audit committee of the board of directors any fraud that involves management or other employees who have a significant role in the issuer's ICFR.

Date: February 15, 2023

<u>/s/ Joseph Fuda</u>

Joseph Fuda

Chief Executive Officer

------

## Exhibit 99.4

------

**FORM 52-109F1**

**CERTIFICATION OF ANNUAL FILINGS**

**FULL CERTIFICATE**

I, Dan Amadori, Chief Financial Officer of Micromem Technologies Inc., certify the following:

1. ***Review:*** I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated by reference in the AIF (together, the "annual filings") of Micromem Technologies Inc. (the "issuer") for the financial year ended October 31, 2022.

2. ***No misrepresentations:*** Based on my knowledge, having exercised reasonable diligence, the annual filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, for the period covered by the annual filings.

3. ***Fair presentation:*** Based on my knowledge, having exercised reasonable diligence, the annual financial statements together with the other financial information included in the annual filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the annual filings.

4. ***Responsibility:*** The issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 *Certification of Disclosure in Issuers' Annual and Interim Filings*, for the issuer.

5. ***Design:*** Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer(s) and I have, as at the financial year end

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.

------

5.1 ***Control framework:*** The control framework the issuer's other certifying officer(s) and I used to design the issuer's ICFR is *Internal Control - Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO").

5.2 **ICFR - material weakness relating to design:** *N/A*

5.3 **Limitation on scope of design:** *N/A*

6. ***Evaluation:*** The issuer's other certifying officer(s) and I have

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) evaluated, or caused to be evaluated under our supervision, the effectiveness of the issuer's DC&P at the financial year end and the issuer has disclosed in its annual MD&A our conclusions about the effectiveness of DC&P at the financial year end based on that evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) evaluated, or caused to be evaluated under our supervision, the effectiveness of the issuer's ICFR at the financial year end and the issuer has disclosed in its annual MD&A.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) our conclusions about the effectiveness of ICFR at the financial year end based on that evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) for each material weakness relating to operation existing at the financial year end

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) a description of the material weakness;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) the impact of the material weakness on the issuer's financial reporting and its ICFR; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C) the issuer's current plans, if any, or any actions already undertaken, for remediating the material weakness.

7. ***Reporting changes in ICFR:*** The issuer has disclosed in its annual MD&A any change in the issuer's ICFR that occurred during the period beginning on August 1, 2022 and ended on October 31, 2022 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.

8. ***Reporting to the issuer's auditors and board of directors or audit committee:*** The issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of ICFR, to the issuer's auditors, and the board of directors or the audit committee of the board of directors any fraud that involves management or other employees who have a significant role in the issuer's ICFR.

Date: February 15, 2023.

<u>/s/ Dan Amadori</u>

Dan Amadori

Chief Financial Officer

------

## Exhibit 99.5

------

***Note: [01 Mar 2017]** - The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative.*

**FORM 13-501F1**

***CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS -***

***PARTICIPATION FEE***

**MANAGEMENT CERTIFICATION**

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br> I, <u>Dan Amadori</u> , an officer of the reporting issuer noted below have examined this Form 13-501F1 (the **Form**) being submitted hereunder to the Alberta Securities Commission and certify that to my knowledge, having exercised reasonable diligence, the information provided in the Form is complete and accurate.  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br> I, <u>Dan Amadori</u> , an officer of the reporting issuer noted below have examined this Form 13-501F1 (the **Form**) being submitted hereunder to the Alberta Securities Commission and certify that to my knowledge, having exercised reasonable diligence, the information provided in the Form is complete and accurate.  |
| &nbsp;&nbsp;<u>/s/Dan Amadori, CFO</u> | <u>February 15, 2023</u> |
| &nbsp;&nbsp;Name: Dan Amadori | Date: |
| &nbsp;&nbsp;Title: CFO |  |

---

---

| | |
|:---|:---|
| **Reporting Issuer Name:** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Micromem Technologies Inc.</u>  |
| **End date of previous financial year:** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>October 31, 2023</u>  |
| **Type of Reporting Issuer:** | **[ X ] Class 1 reporting [ ] Class 3B reporting** |
|  | **issuer issuer** |
| **Highest Trading Marketplace:** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>CSE</u>  |

---

---

| | |
|:---|:---|
| **<u>Market value of listed or quoted equity securities</u>:** | **<u>Market value of listed or quoted equity securities</u>:** |
| **Equity Symbol** | <u>MRM</u> |
| **1st Specified Trading Period (dd/mm/yy)** | <u>November 1, 2021</u> to <u>January 31, 2022</u> |
| Closing price of the security in the class or series on the <br>last trading day of the specified trading period in which <br>such security was listed or quoted on the highest trading <br>marketplace | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$<u>0.075</u> <br> (i) |

---

------

---

| | |
|:---|:---|
| Number of securities in the class or series of such <br>security outstanding at the end of the last trading day<br>of the specified trading period | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$<u>443,044,888</u> <br> (ii<u>)</u> |
| Market value of class or series | (i) x (ii) $<u>33,228,367</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) |

---

---

| | |
|:---|:---|
| **2nd Specified Trading Period (dd/mm/yy)** | <u>February 1, 2022</u> to <u>April 30, 2022</u> |
| Closing price of the security in the class or series on the |  |
| last trading day of the specified trading period in which |  |
| such security was listed or quoted on the highest trading | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$______________________<u>0.05</u> |
| marketplace | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) |
| Number of securities in the class or series of such |  |
| security outstanding at the end of the last trading day of | <u>447191433</u> |
| the specified trading period | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) |
| Market value of class or series | (iii) x (iv) $<u>22,359,572</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) |
| **3rd Specified Trading Period (dd/mm/yy)** | <u>May 1, 2022</u> to <u>July 31, 2022</u> |
| Closing price of the security in the class or series on the |  |
| last trading day of the specified trading period in which |  |
| such security was listed or quoted on the highest trading | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$______________________<u>0.06</u> |
| marketplace | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) |
| Number of securities in the class or series of such |  |
| security outstanding at the end of the last trading day of | <u>459085461</u> |
| the specified trading period | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) |
|  | (v) x (vi) $<u>27,545,128</u> |
| Market value of class or series | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C) |

---

------

---

| | |
|:---|:---|
| **4th Specified Trading Period (dd/mm/yy)** | <u>August 1, 2022</u> to <u>October 31, 2022</u> |
| Closing price of the security in the class or series on the |  |
| last trading day of the specified trading period in which |  |
| such security was listed or quoted on the highest trading | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$<u>0.045</u> |
| marketplace | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) |
| Number of securities in the class or series of such |  |
| security outstanding at the end of the last trading day of | <u>467607678</u> |
| the specified trading period | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) |
|  | (vii) x (viiii) $<u>21,042,346</u> |
| Market value of class or series | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D) |

---

---

| | |
|:---|:---|
| **5th Specified Trading Period (dd/mm/yy)** | _______________ to ______________ |
| Closing price of the security in the class or series on the |  |
| last trading day of the specified trading period in which |  |
| such security was listed or quoted on the highest trading | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$______________________ |
| marketplace | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) |
| Number of securities in the class or series of such |  |
| security outstanding at the end of the last trading day of | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;______________________ |
| the specified trading period | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) |
| Market value of class or series | (ix) x (x) $______________________ |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E) |
| **Average Market Value of Class or Series (Calculate** |  |
| the simple average of the market value of the class or |  |
| series of security for each applicable specified trading | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$<u>26043853</u> |
| period (i.e. A through E above)) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(**1**) |

---

(Repeat the above calculation for each other class or series of equity securities of the reporting issuer (and a subsidiary, if applicable) that was listed or quoted on a marketplace at the end of the previous financial year)

------

**Fair value of outstanding debt securities:**

---

| | |
|:---|:---|
| (Provide details of how value was determined) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $______________________ |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (**2**) |
| **Capitalization for the previous financial year** | (1) + (2) $<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 26,043,853</u> |
| **Participation Fee** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$<u>1200</u> |
| **Late Fee**, if applicable | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$<u> </u> |
| **Total Fee Payable** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$<u>1200</u> |
| (Participation Fee plus Late Fee) |  |

---

------

## Exhibit 99.6

------

**FORM 13-502F1**

**CLASS 1 AND CLASS 3B REPORTING ISSUERS - PARTICIPATION FEE**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**MANAGEMENT CERTIFICATION** | &nbsp;&nbsp;**MANAGEMENT CERTIFICATION** |
| &nbsp;&nbsp;I, <u>Dan Amadori</u> , an officer of the reporting issuer noted below have examined this Form 13-502F1 (the **Form**) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised reasonable diligence, the information provided in the Form is complete and accurate. | &nbsp;&nbsp;I, <u>Dan Amadori</u> , an officer of the reporting issuer noted below have examined this Form 13-502F1 (the **Form**) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised reasonable diligence, the information provided in the Form is complete and accurate. |
| &nbsp;&nbsp; (s)<u>Dan Amadori, CFO</u>  | &nbsp;&nbsp; <u>February 15, 2023</u>  |
| &nbsp;&nbsp; Name: | &nbsp;&nbsp; Date: |
| &nbsp;&nbsp; Title:<br>|  |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp; **Reporting Issuer Name:** | &nbsp;&nbsp; Micromem Technologies Inc. |  |
| &nbsp;&nbsp; **End date of previous financial year:** | &nbsp;&nbsp; October 31, 2022 |  |
| &nbsp;&nbsp; **Type of Reporting Issuer:** | &nbsp;&nbsp; **☑ Class 1 reporting issuer** | &nbsp;&nbsp; **☐ Class 3B reporting issuer** |
| &nbsp;&nbsp; **Highest Trading Marketplace:** | &nbsp;&nbsp; CSE |  |

---

(refer to the definition of "highest trading marketplace" under OSC Rule 13-502 *Fees*)

<u>**Market value of listed or quoted equity securities:**</u>

(in Canadian Dollars - refer to section 7.1 of OSC Rule 13-502 *Fees*)

---

| | |
|:---|:---|
| **Equity Symbol** | <u>MRM</u>  |
| **1<sup>st</sup>** **Specified Trading Period** (dd/mm/yy)****<br> (refer to the definition of "specified trading period" under OSC | <u>November 1, 2021</u> to <u>January 31, 2022</u>  |
| Rule 13-502 *Fees*) |  |
| Closing price of the security in the class or series |  |
| on the last trading day of the specified trading |  |
| period in which such security was listed or quoted |  |
| on the highest trading marketplace | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**<u>$</u>**<u>0.075</u> (i) |
| Number of securities in the class or series of such |  |
| security outstanding at the end of the last trading |  |
| day of the specified trading period | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>443,044,888</u> (ii) |
| Market value of class or series | (i) x (ii) **$** <u>33,228,367</u> (A) |
| **2<sup>nd</sup>** **Specified Trading Period (dd/mm/yy)** |  |
| (refer to the definition of "specified trading period" under OSC | <u>February 1, 2022</u> to <u>April 30, 2022</u>  |
| Rule 13-502 *Fees*) |  |

---

------

---

| | |
|:---|:---|
| Closing price of the security in the class or series |  |
| on the last trading day of the specified trading |  |
| period in which such security was listed or quoted |  |
| on the highest trading marketplace | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$<u>0.05</u> (iii) |
| Number of securities in the class or series of such |  |
| security outstanding at the end of the last trading |  |
| day of the specified trading period | <u>447,191,433</u> (iv) |
| Market value of class or series | (iii) x (iv) **$** <u>22,359,572</u> (B) |
| **3<sup>rd</sup>** **Specified Trading Period (dd/mm/yy)** |  |
| (refer to the definition of "specified trading period" under OSC | <u>May 1, 2022</u> to <u>July 31, 2022</u>  |
| Rule 13-502 *Fees*) |  |
| Closing price of the security in the class or series<br>on the last trading day of the specified trading <br>period in which such security was listed or quoted <br>on the highest trading marketplace | <u>$0.06</u> (v) |
| Number of securities in the class or series of such <br>security outstanding at the end of the last trading <br>day of the specified trading period | <u>447,191,433</u> (vi) |
| Market value of class or series | (v) x (vi) <u>**$** 27,545,128</u> (C) |
| **4<sup>th</sup>** **Specified Trading Period (dd/mm/yy)**<br> (refer to the definition of "specified trading period" under OSC <br>Rule 13-502 *Fees*) | <u>August 1, 2022</u> to <u>October 31, 2022</u> |
| Closing price of the security in the class or series <br>on the last trading day of the specified trading <br>period in which such security was listed or quoted <br>on the highest trading marketplace | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$<u>0.045</u> (vii) |
| Number of securities in the class or series of such <br>security outstanding at the end of the last trading <br>day of the specified trading period | <u>467,607,678</u> (viii) |
| Market value of class or series | (vii) x (viii) **$**<u>21,042,346</u> (D) |
| **5<sup>th</sup>** **Specified Trading Period (dd/mm/yy)**<br> (if applicable - refer to the definition of "specified trading <br>period" under OSC Rule 13-502 *Fees*) | _________________ to _________________ |
| Closing price of the security in the class or series <br>on the last trading day of the specified trading <br>period in which such security was listed or quoted<br>on the highest trading marketplace | **$_______________________ (ix)** |
| Number of securities in the class or series of such<br>security outstanding at the end of the last trading <br>day of the specified trading period | **________________________ (x)** |

---

------

---

| | |
|:---|:---|
| Market value of class or series | (ix) x (x) <u>**$**</u> (D) |
| **Average Market Value of Class or Series**<br> (Calculate the simple average of the market value of the class <br>or series of security for each applicable specified trading <br>period (i.e. A through E above)) | <u>$26,043,853</u> **<u> </u>(1)** |
| **5<sup>th</sup>** **Specified Trading Period (dd/mm/yy)**<br> (if applicable - refer to the definition of "specified trading <br>period" under OSC Rule 13-502 *Fees*) | _________________ to _________________ |
| (Repeat the above calculation for each other class or series of equity securities of the reporting issuer (and a subsidiary pursuant to paragraph 2.8(1)(c) of OSC Rule 13-502 *Fees*, if applicable) that was listed or quoted on a marketplace at the end of the previous financial year) | (Repeat the above calculation for each other class or series of equity securities of the reporting issuer (and a subsidiary pursuant to paragraph 2.8(1)(c) of OSC Rule 13-502 *Fees*, if applicable) that was listed or quoted on a marketplace at the end of the previous financial year) |

---

---

| | |
|:---|:---|
| **Fair value of outstanding debt securities:**(See paragraph 2.8(1)(b)*,* and if applicable, paragraph 2.8(1)(c) |  |
| of OSC Rule 13-502 *Fees*) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**$_________________________ (2)** |
| (Provide details of how value was determined) |  |
| **Capitalization for the previous financial year** | (1) + (2) **<u>$26,043,853</u>________________** |
| **Participation Fee** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**$**<u>2590</u>  |
| (For Class 1 reporting issuers, from Appendix A of |  |
| OSC Rule 13-502 *Fees*, select the participation fee) |  |
| (For Class 3B reporting issuers, from Appendix |  |
| A.1 of OSC Rule 13-502 *Fees*, select the |  |
| participation fee) |  |
| **Late Fee**, if applicable |  |
| (As determined under section 2.7 of OSC Rule 13- |  |
| 502 *Fees*) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**$**_________________________ |
| **Total Fee Payable** |  |
| (Participation Fee plus Late Fee) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**$**<u>2590</u>  |

---

------